WO2023280295A1 - 一类苯并七元环类化合物及其应用 - Google Patents

一类苯并七元环类化合物及其应用 Download PDF

Info

Publication number
WO2023280295A1
WO2023280295A1 PCT/CN2022/104551 CN2022104551W WO2023280295A1 WO 2023280295 A1 WO2023280295 A1 WO 2023280295A1 CN 2022104551 W CN2022104551 W CN 2022104551W WO 2023280295 A1 WO2023280295 A1 WO 2023280295A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
cycloalkyl
substituted
alkyl
formula
Prior art date
Application number
PCT/CN2022/104551
Other languages
English (en)
French (fr)
Inventor
王奎锋
李家鹏
张涛
Original Assignee
勤浩医药（苏州）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 勤浩医药（苏州）有限公司 filed Critical 勤浩医药（苏州）有限公司
Publication of WO2023280295A1 publication Critical patent/WO2023280295A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/14—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with at least one hydroxy group on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/64—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/14—Preparation of carboxylic acid esters from carboxylic acid halides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered

Definitions

  • the invention belongs to the field of medicine, and relates to a benzo seven-membered ring compound and its preparation method and application.
  • the invention discloses that it is used as a regulator after estrogen failure to prevent and/or treat estrogen receptor-mediated or dependent diseases and disorders.
  • estrogen receptor positive (ER+) subgroup accounts for about 75%. Due to the important role of estrogen receptors in the tumors of these patients, the current main treatment is to target this signaling pathway, including the use of aromatase inhibitors such as exemestane, letrozole, and anastrozole to inhibit estrogen Synthetic, direct inhibition of estrogen receptor function using an estrogen receptor modulator (SERM) such as tamoxifen or the degrader (SERD) fulvestrant.
  • SERM estrogen receptor modulator
  • SELD degrader
  • irreversible inhibitors are an important idea to solve drug resistance.
  • a more classic example is the development of the EGFR receptor irreversible inhibitor afatinib (launched in 2013), the electrophilic active group acrylamide in its structure and the cysteine residue in the EGFR receptor active site (Mulcapto group) forms a covalent bond, overcomes the drug resistance problem of the first generation of EGFR (gefitinib, erlotinib, etc.) receptor inhibitors, and also shows good performance on non-drug-resistant EGFR receptors activity.
  • the idea of irreversible inhibition is also promising for drug development in drug-resistant ER+ patients.
  • the present invention provides a class of benzo seven-membered ring compounds capable of preventing and/or treating estrogen receptor-mediated or dependent diseases and conditions.
  • the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope labeling thereof, the compound of formula (I)
  • the structure is:
  • Each R 1 is independently selected from -H, D, -OH, -NH 2 , -COOH, -CH 2 NH 2 and -CH 2 OH;
  • R is selected from substituted or unsubstituted aryl, heterocyclyl and heteroaryl ;
  • R 4 , R 5 , R 6 , R 7 are each independently selected from -H, D, alkyl, cycloalkyl and heterocyclyl;
  • R 4 and R 5 and the connected nitrogen atom form a 3-7 membered heterocyclic group
  • R 6 and R 7 and the connected carbon atom form a C 3-6 cycloalkyl group or a 3-7 membered heterocyclic group
  • p is selected from 0, 1, 2 and 3;
  • Z is selected from O, S, CHR 11 and NH, R 11 can be H, OH, D, NH 2 and C 1-3 alkyl;
  • Y is selected from -R 8 NH-, -(CR 9 R 10 ) q NH- and 3-7 membered nitrogen-containing heterocyclic groups, wherein,
  • R 8 is C 3-6 cycloalkyl or 3-7 membered heterocyclic group
  • Each R 9 and R 10 are independently selected from -H, a halogen atom, substituted or unsubstituted C 1-6 alkyl and C 3-6 cycloalkyl; or R 9 and R 10 and the carbon atom connected to it Forming a substituted or unsubstituted C 3-6 cycloalkyl group or a 3-7 membered heterocyclic group; or R 9 or R 10 , forming a carbon atom with R 9 or R 10 and a carbon atom adjacent to the carbon atom C 3-6 cycloalkyl;
  • q is selected from 1,2,3,4 and 5;
  • n is selected from 1,2,3 and 4.
  • R 2 is selected from substituted or unsubstituted phenyl, 3-9 membered heterocyclic group and 5-10 membered heteroaryl group, and the substitution is selected from C 1-6 alkyl, halogen atom, -NH 2.
  • substituents in a 10-membered heteroaryl group or a 3-7-membered heterocyclic group are optionally substituted by 1-3 selected from C 1-6 alkyl groups, halogen atoms, -NH 2 , -CN, -COOH, -CHO, -OH, -NO 2 , C 1-6 alkoxy, C 1-6 alkylamino, C 3-6 cycloalkyl.
  • the 3-9 membered heterocyclic group is selected from aziridinyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, morpholine Base, piperazinyl, thiomorpholinyl, tetrahydropyranyl, 1,1-dioxothiomorpholinyl, butyrolactam, valerolactam, caprolactam, butyrolactone, valerolactam Any of ester group, caprolactone group, 2,3-dihydro-1H-indolyl group and benzodioxolanyl group;
  • the 5-10 membered heteroaryl group contains 1-3 heteroatoms optionally selected from N, NH, O, S; preferably, the 5-10 membered heteroaryl ring is selected from thienyl, pyridyl, pyrimidyl , pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, imidazolyl, tetrazolyl, isothiazolyl , oxazolyl, isoxazolyl, thiadiazolyl, oxadiazolyl, benzothienyl, indolyl, benzimidazolyl, benzothiazolyl, benzopyrazole, benzofuryl, benzene Any of oxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl,
  • R 4 , R 5 , R 6 , and R 7 are independently selected from -H, D, C 1-3 alkyl, C 3-6 cycloalkyl and 5-6 membered heterocyclyl;
  • R 4 and R 5 and the connected nitrogen atom form a 5-6 membered heterocyclic group
  • Y is selected from -R 8 NH-, -(CR 9 R 10 ) q NH- and 4-6 membered nitrogen-containing heterocyclic groups, wherein,
  • R 8 is C 3-6 cycloalkyl or 4-6 membered heterocyclic group
  • Each R 9 and R 10 are independently selected from -H, a halogen atom, substituted or unsubstituted C 1-6 alkyl and C 3-6 cycloalkyl; or R 9 and R 10 and the carbon atom connected to it Form a C 3-6 cycloalkyl group or a 3-7 membered heterocyclic group; or R 9 or R 10 , the carbon atom of R 9 or R 10 and the carbon atom adjacent to the carbon atom form a C 3-6 ring Alkyl; the substituted C 1-6 alkyl and C 3-6 cycloalkyl are selected from halogen atoms, -NH 2 , -CN, -COOH, -CHO, -OH, -NO 2 , C 1 Substituents of -6 alkoxy and C 1-6 alkylamino;
  • q is selected from 1, 2 and 3, preferably 2.
  • substitution is selected from C 1-6 alkyl, halogen atom, -NH 2 , -CN, -COOH, - CHO, -OH, -NO 2 , C 1-6 alkoxy, C 1-6 alkylamino, C 3-6 cycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl or 3-7
  • substituents in the membered heterocyclic group are substituted, and the substituents are optionally 1-3 selected from C 1-6 alkyl, halogen atom, -NH 2 , -CN, -COOH, -CHO, -OH, -NO 2 , C 1-6 alkoxy, C 1-6 alkylamino, C 3-6 cycloalkyl.
  • the substitution is selected from C 1-6 alkyl, halogen atom, -NH 2 , -CN, -COOH, -CHO, -OH, -NO 2 ,
  • C 1-6 alkoxy, C 1-6 alkylamino, C 3-6 cycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl or 3-7 membered heterocyclic group substituents the substituents are optionally 1-3 selected from C 1-6 alkyl, halogen atom, -NH 2 , -CN, -COOH, -CHO, -OH, -NO 2 , C 1 -6 alkoxy, C 1-6 alkylamino, C 3-6 cycloalkyl substituted.
  • R 1 is independently selected from -H, -OH and -NH 2 ;
  • R 2 is selected from substituted or unsubstituted phenyl, C 5-10 heteroaryl; the replacement is selected from halogen, cyano, C 1-3 alkoxy, halogen substituted C 1-3 alkoxy replaced by substituents;
  • R 4 and R 5 are independently selected from -H and C 1-3 alkyl; or R 4 and R 5 and the connected nitrogen atom form pyrrolidinyl or piperidinyl;
  • Z is selected from O, S and NH
  • Y is selected from -R 8 NH-, -(CR 9 R 10 ) q NH- and 3-7 membered nitrogen-containing heterocyclic groups, wherein,
  • R 8 is C 3-6 cycloalkyl
  • Each R 9 and R 10 are independently selected from -H, a halogen atom, a C 1-3 alkyl group; or R 9 and R 10 and the carbon atom connected to it form a C 3-6 cycloalkyl group;
  • It is selected from substituted or unsubstituted phenyl and pyridyl, and the substitution is substituted by a substituent selected from -H, a halogen atom and a C 1-3 alkoxy group.
  • the present invention also provides a compound or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope labeling thereof, characterized in that the compound is selected from:
  • the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) described above or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope label .
  • the present invention also provides a compound of formula (I) described above or its pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope label, or the pharmaceutical composition , for use in the prevention and/or treatment of estrogen receptor mediated or dependent diseases and conditions.
  • the present invention also provides a compound of formula (I) described above or its pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope label, or the pharmaceutical composition Use for preventing and/or treating estrogen receptor-mediated or dependent diseases and conditions.
  • the present invention also provides a compound of formula (I) described above or its pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope label, or the pharmaceutical composition Application in the preparation of medicaments for preventing and/or treating estrogen receptor-mediated or dependent diseases and conditions, preferably, the disease is breast cancer.
  • the present invention also provides a method for preventing and/or treating estrogen receptor-mediated or dependent diseases and disorders, which comprises the following steps: injecting a therapeutically effective amount of any one of the formulas described above ( I)
  • the compound or its pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope label, or the pharmaceutical composition is administered to patients in need thereof.
  • the present invention also provides a drug combination form, which comprises any one of the above-mentioned compounds of formula (I) or pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotope labels , or the pharmaceutical composition, and at least one additional therapeutic agent.
  • a class of benzo seven-membered ring compounds provided by the present invention has a good ability to selectively inhibit the activity of estrogen receptors and has the ability to inhibit human breast cancer cell lines MCF of estrogen receptor wild type, Y537S and D538G mutants. -7 cell line anti-proliferation activity, the compound provided by the present invention can be used for preventing and/or treating estrogen receptor-mediated or dependent diseases and conditions.
  • the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope labeling thereof, the structure of the compound of formula (I) is:
  • Each R 1 is independently selected from -H, D, -OH, -NH 2 , -COOH, -CH 2 NH 2 and -CH 2 OH;
  • R is selected from substituted or unsubstituted aryl, heterocyclyl and heteroaryl ;
  • R 4 , R 5 , R 6 , R 7 are each independently selected from -H, D, alkyl, cycloalkyl and heterocyclyl;
  • R 4 and R 5 and the connected nitrogen atom form a 3-7 membered heterocyclic group
  • R 6 and R 7 and the connected carbon atom form a C 3-6 cycloalkyl group or a 3-7 membered heterocyclic group
  • p is selected from 0, 1, 2 and 3;
  • Z is selected from O, S, CHR 11 and NH, R 11 can be H, OH, D, NH 2 and C 1-3 alkyl;
  • Y is selected from -R 8 NH-, -(CR 9 R 10 ) q NH- and 3-7 membered nitrogen-containing heterocyclic groups, wherein,
  • R 8 is C 3-6 cycloalkyl or 3-7 membered heterocyclic group
  • Each R 9 and R 10 are independently selected from -H, a halogen atom, substituted or unsubstituted C 1-6 alkyl and C 3-6 cycloalkyl; or R 9 and R 10 and the carbon atom connected to it Forming a substituted or unsubstituted C 3-6 cycloalkyl group or a 3-7 membered heterocyclic group; or R 9 or R 10 , forming a carbon atom with R 9 or R 10 and a carbon atom adjacent to the carbon atom C 3-6 cycloalkyl;
  • q is selected from 1,2,3,4 and 5;
  • n is selected from 1,2,3 and 4.
  • R 2 is selected from substituted or unsubstituted phenyl, 3-9 membered heterocyclyl and 5-10 membered heteroaryl, and the substitution is selected from C 1-6 alkyl , halogen atom, -NH 2 , -CN, -COOH, -CHO, -OH, -NO 2 , C 1-6 alkoxy, C 1-6 alkylamino, C 3-6 cycloalkyl, C 6- 10 aryl, 5-10 membered heteroaryl or 3-7 membered heterocyclic group substituted by one or more substituents, the above substituents are optionally 1-3 selected from C 1-6 alkyl, halogen atom, -NH 2 , -CN, -COOH, -CHO, -OH, -NO 2 , C 1-6 alkoxy, C 1-6 alkylamino, C 3-6 cycloalkyl.
  • the 3-9 membered heterocyclic group is selected from aziridinyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, Piperidinyl, morpholinyl, piperazinyl, thiomorpholinyl, tetrahydropyranyl, 1,1-dioxothiomorpholinyl, butyrolactam, valerolactam, caprolactam, butyrolactam Any of lactone, valerolactone, caprolactone, 2,3-dihydro-1H-indolyl and benzodioxolanyl;
  • the 5-10 membered heteroaryl group contains 1-3 heteroatoms optionally selected from N, NH, O, S; preferably, the 5-10 membered heteroaryl ring is selected from thienyl, pyridyl, pyrimidyl , pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, imidazolyl, tetrazolyl, isothiazolyl , oxazolyl, isoxazolyl, thiadiazolyl, oxadiazolyl, benzothienyl, indolyl, benzimidazolyl, benzothiazolyl, benzopyrazole, benzofuryl, benzene Any of oxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl,
  • R 4 , R 5 , R 6 , and R 7 are independently selected from -H, D, C 1-3 alkyl, C 3-6 cycloalkyl and 5-6 membered heterocyclyl;
  • R 4 and R 5 and the connected nitrogen atom form a 5-6 membered heterocyclic group
  • Y is selected from -R 8 NH-, -(CR 9 R 10 ) q NH- and 4-6 membered nitrogen-containing heterocyclic groups, wherein,
  • R 8 is C 3-6 cycloalkyl or 4-6 membered heterocyclic group
  • Each R 9 and R 10 are independently selected from -H, a halogen atom, substituted or unsubstituted C 1-6 alkyl and C 3-6 cycloalkyl; or R 9 and R 10 and the carbon atom connected to it Form a C 3-6 cycloalkyl group or a 3-7 membered heterocyclic group; or R 9 or R 10 , the carbon atom of R 9 or R 10 and the carbon atom adjacent to the carbon atom form a C 3-6 ring Alkyl; the substituted C 1-6 alkyl and C 3-6 cycloalkyl are selected from halogen atoms, -NH 2 , -CN, -COOH, -CHO, -OH, -NO 2 , C 1 Substituents of -6 alkoxy and C 1-6 alkylamino;
  • q is selected from 1, 2 and 3, preferably 2.
  • substitution is selected from C 1-6 alkyl, halogen atom, -NH 2 , -CN, -COOH, - CHO, -OH, -NO 2 , C 1-6 alkoxy, C 1-6 alkylamino, C 3-6 cycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl or 3-7
  • substituents in the membered heterocyclic group are substituted, and the substituents are optionally 1-3 selected from C 1-6 alkyl, halogen atom, -NH 2 , -CN, -COOH, -CHO, -OH, -NO 2 , C 1-6 alkoxy, C 1-6 alkylamino, C 3-6 cycloalkyl.
  • the above-mentioned selected from substituted or unsubstituted phenyl and pyridyl the substitution is selected from C 1-6 alkyl, halogen atom, -NH 2 , -CN, -COOH, -CHO, -OH, -NO 2 ,
  • the substituents are optionally 1-3 selected from C 1-6 alkyl, halogen atom, -NH 2 , -CN, -COOH, -CHO, -OH, -NO 2 , C 1 -6 alkoxy, C 1-6 alkylamino, C 3-6 cycloalkyl substituted.
  • R 1 is independently selected from -H, -OH and -NH 2 ;
  • R 2 is selected from substituted or unsubstituted phenyl, C 5-10 heteroaryl; the replacement is selected from halogen, cyano, C 1-3 alkoxy, halogen substituted C 1-3 alkoxy replaced by substituents;
  • R 4 and R 5 are independently selected from -H and C 1-3 alkyl; or R 4 and R 5 and the connected nitrogen atom form pyrrolidinyl or piperidinyl;
  • Z is selected from O, S and NH
  • Y is selected from -R 8 NH-, -(CR 9 R 10 ) q NH- and 3-7 membered nitrogen-containing heterocyclic groups, wherein,
  • R 8 is C 3-6 cycloalkyl
  • Each R 9 and R 10 are independently selected from -H, a halogen atom, a C 1-3 alkyl group; or R 9 and R 10 and the carbon atom connected to it form a C 3-6 cycloalkyl group;
  • It is selected from substituted or unsubstituted phenyl and pyridyl, and the substitution is substituted by a substituent selected from -H, a halogen atom and a C 1-3 alkoxy group.
  • the present invention also provides a compound or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope labeling thereof, characterized in that the compound is selected from:
  • the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) described above or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope label .
  • the present invention also provides a compound of formula (I) described above or its pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope label, or the pharmaceutical composition , for use in the prevention and/or treatment of estrogen receptor mediated or dependent diseases and conditions.
  • the present invention also provides a compound of formula (I) described above or its pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope label, or the pharmaceutical composition Use for preventing and/or treating estrogen receptor-mediated or dependent diseases and conditions.
  • the present invention also provides a compound of formula (I) described above or its pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope label, or the pharmaceutical composition Application in preparation of medicines for preventing and/or treating estrogen receptor-mediated or dependent diseases and conditions.
  • the present invention also provides a method for preventing and/or treating estrogen receptor-mediated or dependent diseases and disorders, which comprises the following steps: injecting a therapeutically effective amount of any one of the formulas described above ( I)
  • the compound or its pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope label, or the pharmaceutical composition is administered to patients in need thereof.
  • the present invention also provides a drug combination form, which comprises any one of the above-mentioned compounds of formula (I) or pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotopes thereof A marker, or the pharmaceutical composition, and at least one additional therapeutic agent.
  • halogen atom means fluorine, chlorine, bromine or iodine alone or in combination, especially fluorine, chlorine or bromine.
  • C 1-6 alkyl alone or in combination means a saturated linear or branched alkyl group containing 1-6 carbon atoms, including methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl -1-butyl, 2-methyl-1-butyl, n-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl Base-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3,-dimethyl-2 - Butyl, etc.
  • C 1-6 alkyl is any one of methyl, ethyl, n-propyl, isopropyl and tert-butyl.
  • C 1-3 alkyl alone or in combination means a saturated linear or branched alkyl group containing 1-3 carbon atoms, including methyl, ethyl, n-propyl, isopropyl Wait.
  • C 1-6 alkoxy means the group C 1-6 alkyl-O-, wherein "C 1-6 alkyl” means as defined above, including (but not limited to) Methoxy (-OCH 3 ), Ethoxy (-OCH 2 CH 3 ), n-Propoxy (-OCH 2 CH 2 CH 3 ), Isopropoxy (-OCH(CH 3 ) 2 ), n-Butyl Oxygen (-OCH 2 CH 2 CH 2 CH 3 ), sec-butoxy (-OCH(CH 3 )CH 2 CH 3 ), isobutoxy (-OCH 2 CH(CH 3 ) 2 ), tert-butoxy (-OC(CH 3 ) 3 ), n-pentyloxy (-OCH 2 CH 2 CH 2 CH 2 CH 3 ), neopentyloxy (-OCH 2 C(CH 3 ) 3 ), etc.
  • C 3-6 cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cycloalkyl group with 3 to 6 carbon atoms alone or in combination, including cyclopropyl, cyclobutyl, cyclopentyl base, cyclohexyl, cycloheptyl, etc.
  • heterocyclic group means a saturated or partially unsaturated monocyclic or polycyclic heterocyclic group formed by replacing a carbon atom on the ring with at least one heteroatom selected from sulfur, oxygen or nitrogen.
  • group refers to a saturated or partially unsaturated monocyclic or polycyclic heterocyclic group containing 3-9, especially 3-7 carbon atoms and a heteroatom or a heteroatom group, and the heteroatom or heteroatom group selected from N, NH, O, C(O), S(O) m (wherein m is 0, 1 or 2); the 3-9 membered heterocyclic group includes aziridinyl, azetidinyl, Oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, morpholinyl, piperazinyl, thiomorpholinyl, tetrahydropyranyl, 1,1-
  • 3-9 membered heterocyclic group is similar to the definition of the term “3-9 membered heterocyclic group”, which refers to a saturated or partially unsaturated monocyclic ring containing 5-6 carbon atoms and heteroatoms or heteroatom groups or polycyclic heterocyclyl
  • aryl means any stable 6-10 membered monocyclic or bicyclic aromatic group, including phenyl, naphthyl, tetrahydronaphthyl, 2,3-indanyl or biphenyl and the like.
  • the hydrogen atoms on “aryl” are independently optionally substituted with one or more substituents described herein.
  • heteroaryl means an aromatic ring group formed by replacing a carbon atom on the ring with at least one heteroatom selected from sulfur, oxygen or nitrogen.
  • This aromatic ring group can be a 5-7 membered monocyclic ring or a 7-12 bicyclic group.
  • the number of heteroatoms in the heteroaryl group is preferably 1, 2, 3 or 4, for example, the 5-10 membered heteroaryl ring is selected from thienyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl , pyrrolyl, pyrazolyl, thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, imidazolyl, tetrazolyl, isothiazolyl, oxazolyl, isoxazole base, thiadiazolyl, oxadiazolyl, benzothienyl, benzopyrazole, indolyl, benzimidazolyl, benzothiazolyl, benzofuryl, benzoxazolyl, benziso Any of oxazolyl, quinolinyl, isoquinolyl, quinazolinyl, indazolyl or indo[
  • C 6-10 aryl means an aryl group having 6-10 carbon atoms, wherein aryl means as defined above.
  • heteroaryl denotes a heteroaryl ring having 5-10 carbon atoms and heteroatoms, wherein heteroaryl ring means as defined above.
  • amino alone or in combination denotes a primary (-NH 2 ), secondary (-NH-) or tertiary amino group
  • C 1-6 alkylamino alone or in combination, means an amino group as defined above, wherein the hydrogen atom of the amino group is replaced by at least one C 1-6 alkyl group, wherein "C 1-6 alkyl "Represents as defined above, correspondingly, "C 1-6 alkylamino” includes methylamino, ethylamino, propylamino, isopropylamino, n-butylamino, isobutylamino, 2- Butylamino, tert-butylamino, n-pentylamino, 2-pentylamino, 3-pentylamino, 2-methyl-2-butylamino, 3-methyl-2-butylamino, 3- Methyl-1-butylamino, 2-methyl-1-butylamino, n-hexylamino, 2-hexylamino, 3-hexylamino, 2-methyl-2-pentylamino, 3-methyl- 2-Pent
  • isomeric forms including enantiomers, diastereomers, tautomers and geometric isomers (including cis and trans isomers). Therefore, the individual stereochemical isomers of the compounds contemplated in the present invention or their enantiomers, diastereomers, tautomers or geometric isomers (or cis-trans isomers) Mixtures are within the scope of the present invention.
  • pharmaceutically acceptable salt means that the compounds of the present invention exist in the form of their pharmaceutically acceptable salts, including acid addition salts and base addition salts.
  • Pharmaceutically acceptable salts are described in pharmaceutically salts by SM Berge in J. Pharmaceutical Sciences (Vol. 66: 1-19, 1977).
  • the pharmaceutically acceptable non-toxic acid addition salt means the salt formed by the compound in the present invention and organic or inorganic acid
  • organic or inorganic acid includes but not limited to hydrochloric acid, sulfuric acid, hydrobromic acid, hydrogen iodide acid, phosphoric acid, nitric acid, perchloric acid, acetic acid, oxalic acid, maleic acid, fumaric acid, tartaric acid, benzenesulfonic acid, methanesulfonic acid, salicylic acid, succinic acid, citric acid, lactic acid, propionic acid, benzoic acid, p-toluenesulfonic acid, malic acid, etc.
  • Non-toxic base addition salts refer to salts formed by the compounds of the present invention with organic or inorganic bases, including but not limited to alkali metal salts such as lithium, sodium or potassium salts; alkaline earth metal salts such as calcium or magnesium salts; organic base salts, such as ammonium salts or N + (C 1-6 alkyl) 4 salts formed by organic bases containing N groups, preferably lithium hydroxide, sodium hydroxide, potassium hydroxide, Sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, calcium carbonate, ammonia water, triethylamine, tetrabutylammonium hydroxide, etc.
  • alkali metal salts such as lithium, sodium or potassium salts
  • alkaline earth metal salts such as calcium or magnesium salts
  • organic base salts such as ammonium salts or N + (C 1-6 alkyl) 4 salts formed by organic bases containing N groups, preferably lithium hydroxide, sodium hydroxide, potassium hydrox
  • solvate means an association of one or more solvent molecules with a compound of the present invention.
  • Solvents that form solvates include, but are not limited to, water, methanol, ethanol, isopropanol, ethyl acetate, tetrahydrofuran, N,N-dimethylformamide, dimethylsulfoxide, and the like.
  • “Pharmaceutically acceptable salts” can be synthesized by common chemical methods.
  • esters are used to denote organic esters, including monoesters, diesters, triesters, and more generally polyesters.
  • prodrug refers to a chemical derivative of the compound of the present invention, which is converted into a compound represented by general formula I through a chemical reaction in vivo.
  • isotopic derivative means that the hydrogen atom in the general formula (I) is replaced by 1-6 deuterium atoms (D), and the carbon atom in the general formula (I) is replaced by 1-3 carbon 14 Isotopic derivatives obtained by substitution of atoms ( 14 C).
  • tribromopyridinium salt (10.4g, 32.4mmol, 1.05eq.) was added to a solution of compound 001-10 (14.8g, 30.9mmol, 1.0eq.) in tetrahydrofuran (200mL), and the reaction mixture was The reaction was continued for one hour at room temperature.
  • the reaction mixture was added to a saturated sodium bicarbonate (100 mL) solution, the above mixture was extracted with dichloromethane (100 mL*2), the organic phases were combined, washed with saturated brine, and dried over magnesium sulfate.
  • the crude product obtained by concentration was subjected to column chromatography to obtain the white solid product 001-11 (11.5 g, 20.6 mmol, 66.7%).
  • Trifluoroacetic acid (1.54g, 13.5mmol, 1.0mL, 15.9eq.) was added to a solution of compound 001-12 (500mg, 850.8umol, 1.0eq.) in dichloromethane (5mL), and the reaction compound was reacted at room temperature for two Hour. The reaction was also concentrated to obtain yellow solid product 001-13 (500 mg, 831.1 ⁇ mol, 97.7%), which was directly used in the next reaction.
  • LCMS conditions mobile phase: 0.02% ammonia water (mobile phase A), acetonitrile (mobile phase B), after three minutes mobile phase B from 10% to 80%, keep 80% mobile phase B for 0.5 minutes, flow rate: 1.0ml /min; Chromatographic column: Xbrige Shield RP-18, 5um, 2.1*50mm; Detection wavelength: UV 220nm and 254nm; Column temperature: 50°C.
  • Liquid phase mass spectrometry (LC-MS) conditions 0.037% trifluoroacetic acid aqueous solution (mobile phase A), 0.018% trifluoroacetic acid acetonitrile solution (mobile phase B), mobile phase B after 3 minutes from 5%-80%, Keep 80% mobile phase B for 0.5 minutes; flow rate: 1mL/min; column: C18 2.1*30mm, 3um; detection wavelength: UV 220nm and 254nm; column temperature: 50°C; mass spectrometry ion source: ESI.
  • Example 1 a white solid compound 003 was synthesized.
  • Liquid phase mass spectrometry (LC-MS) conditions 0.037% trifluoroacetic acid aqueous solution (mobile phase A), 0.018% trifluoroacetic acid acetonitrile solution (mobile phase B), mobile phase B after 3 minutes from 5%-80%, Keep 80% mobile phase B for 0.5 minutes; flow rate: 1mL/min; column: C18 2.1*30mm, 3um; detection wavelength: UV 220nm and 254nm; column temperature: 50°C; mass spectrometry ion source: ESI.
  • Example 1 a white solid compound 004 was synthesized.
  • LCMS conditions mobile phase: 0.02% ammonia water (mobile phase A), acetonitrile (mobile phase B), after six minutes mobile phase B from 10% to 80%, keep 80% mobile phase B for one minute, flow rate: 1.0ml/ min; Chromatographic column: Xbrige Shield RP-18, 5um, 2.1*50mm; Detection wavelength: 220nm and 254nm; Column temperature: 45°C.
  • Example 1 a white solid compound 005 was synthesized.
  • Liquid phase mass spectrometry (LC-MS) conditions 0.037% trifluoroacetic acid aqueous solution (mobile phase A), 0.018% trifluoroacetic acid acetonitrile solution (mobile phase B), mobile phase B after 3 minutes from 5%-80%, Keep 80% mobile phase B for 0.5 minutes; flow rate: 1mL/min; column: C18 2.1*30mm, 3um; detection wavelength: UV 220nm and 254nm; column temperature: 50°C; mass spectrometry ion source: ESI.
  • Example 1 a white solid compound 006 was synthesized.
  • Liquid phase mass spectrometry (LC-MS) conditions 0.037% trifluoroacetic acid aqueous solution (mobile phase A), 0.018% trifluoroacetic acid acetonitrile solution (mobile phase B), mobile phase B after 3 minutes from 5%-80%, Keep 80% mobile phase B for 0.5 minutes; flow rate: 1mL/min; column: C18 2.1*30mm, 3um; detection wavelength: UV 220nm and 254nm; column temperature: 50°C; mass spectrometry ion source: ESI.
  • Example 1 a white solid compound 007 was synthesized.
  • Liquid phase mass spectrometry (LC-MS) conditions 0.037% trifluoroacetic acid aqueous solution (mobile phase A), 0.018% trifluoroacetic acid acetonitrile solution (mobile phase B), mobile phase B after 3 minutes from 5%-80%, Keep 80% mobile phase B for 0.5 minutes; flow rate: 1mL/min; column: C18 2.1*30mm, 3um; detection wavelength: UV 220nm and 254nm; column temperature: 50°C; mass spectrometry ion source: ESI.
  • Example 1 a white solid compound 008 was synthesized.
  • Liquid phase mass spectrometry (LC-MS) conditions 0.037% trifluoroacetic acid aqueous solution (mobile phase A), 0.018% trifluoroacetic acid acetonitrile solution (mobile phase B), mobile phase B after 3 minutes from 5%-80%, Keep 80% mobile phase B for 0.5 minutes; flow rate: 1mL/min; column: C18 2.1*30mm, 3um; detection wavelength: UV 220nm and 254nm; column temperature: 50°C; mass spectrometry ion source: ESI.
  • Liquid phase mass spectrometry (LC-MS) conditions 0.037% trifluoroacetic acid aqueous solution (mobile phase A), 0.018% trifluoroacetic acid acetonitrile solution (mobile phase B), mobile phase B after 3 minutes from 5%-80%, Keep 80% mobile phase B for 0.5 minutes; flow rate: 1mL/min; column: C18 2.1*30mm, 3um; detection wavelength: UV 220nm and 254nm; column temperature: 50°C; mass spectrometry ion source: ESI.
  • Example 1 a white solid compound 010 was synthesized.
  • Liquid phase mass spectrometry (LC-MS) conditions 0.037% trifluoroacetic acid aqueous solution (mobile phase A), 0.018% trifluoroacetic acid acetonitrile solution (mobile phase B), mobile phase B after 3 minutes from 5%-80%, Keep 80% mobile phase B for 0.5 minutes; flow rate: 1mL/min; column: C18 2.1*30mm, 3um; detection wavelength: UV 220nm and 254nm; column temperature: 50°C; mass spectrometry ion source: ESI.
  • Example 1 a white solid compound 011 was synthesized.
  • Liquid phase mass spectrometry (LC-MS) conditions 0.037% trifluoroacetic acid aqueous solution (mobile phase A), 0.018% trifluoroacetic acid acetonitrile solution (mobile phase B), mobile phase B after 3 minutes from 5%-80%, Keep 80% mobile phase B for 0.5 minutes; flow rate: 1mL/min; column: C18 2.1*30mm, 3um; detection wavelength: UV 220nm and 254nm; column temperature: 50°C; mass spectrometry ion source: ESI.
  • LCMS conditions mobile phase: 0.02% ammonia water (mobile phase A), acetonitrile (mobile phase B), after three minutes mobile phase B from 10% to 80%, keep 80% mobile phase B for 0.5 minutes, flow rate: 1.0ml /min; Chromatographic column: Xbrige Shield RP-18, 5um, 2.1*50mm; Detection wavelength: UV 220nm and 254nm; Column temperature: 50°C.
  • Liquid phase mass spectrometry (LC-MS) conditions 0.037% trifluoroacetic acid aqueous solution (mobile phase A), 0.018% trifluoroacetic acid acetonitrile solution (mobile phase B), mobile phase B after 3 minutes from 5%-80%, Keep 80% mobile phase B for 0.5 minutes; flow rate: 1mL/min; column: C18 2.1*30mm, 3um; detection wavelength: UV 220nm and 254nm; column temperature: 50°C; mass spectrometry ion source: ESI.
  • Example 11 a white solid compound 014 was synthesized.
  • Liquid phase mass spectrometry (LC-MS) conditions 0.037% trifluoroacetic acid aqueous solution (mobile phase A), 0.018% trifluoroacetic acid acetonitrile solution (mobile phase B), mobile phase B after 3 minutes from 5%-80%, Keep 80% mobile phase B for 0.5 minutes; flow rate: 1mL/min; column: C18 2.1*30mm, 3um; detection wavelength: UV 220nm and 254nm; column temperature: 50°C; mass spectrometry ion source: ESI.
  • Example 11 a white solid compound 015 was synthesized.
  • Liquid phase mass spectrometry (LC-MS) conditions 0.037% trifluoroacetic acid aqueous solution (mobile phase A), 0.018% trifluoroacetic acid acetonitrile solution (mobile phase B), mobile phase B after 3 minutes from 5%-80%, Keep 80% mobile phase B for 0.5 minutes; flow rate: 1mL/min; column: C18 2.1*30mm, 3um; detection wavelength: UV 220nm and 254nm; column temperature: 50°C; mass spectrometry ion source: ESI.
  • Example 11 a white solid compound 016 was synthesized.
  • Liquid phase mass spectrometry (LC-MS) conditions 0.037% trifluoroacetic acid aqueous solution (mobile phase A), 0.018% trifluoroacetic acid acetonitrile solution (mobile phase B), mobile phase B after 3 minutes from 5%-80%, Keep 80% mobile phase B for 0.5 minutes; flow rate: 1mL/min; column: C18 2.1*30mm, 3um; detection wavelength: UV 220nm and 254nm; column temperature: 50°C; mass spectrometry ion source: ESI.
  • Example 11 a white solid compound 017 was synthesized.
  • Liquid phase mass spectrometry (LC-MS) conditions 0.037% trifluoroacetic acid aqueous solution (mobile phase A), 0.018% trifluoroacetic acid acetonitrile solution (mobile phase B), mobile phase B after 3 minutes from 5%-80%, Keep 80% mobile phase B for 0.5 minutes; flow rate: 1mL/min; column: C18 2.1*30mm, 3um; detection wavelength: UV 220nm and 254nm; column temperature: 50°C; mass spectrometry ion source: ESI.
  • Liquid phase mass spectrometry (LC-MS) conditions 0.037% trifluoroacetic acid aqueous solution (mobile phase A), 0.018% trifluoroacetic acid acetonitrile solution (mobile phase B), mobile phase B after 3 minutes from 5%-80%, Keep 80% mobile phase B for 0.5 minutes; flow rate: 1mL/min; column: C18 2.1*30mm, 3um; detection wavelength: UV 220nm and 254nm; column temperature: 50°C; mass spectrometry ion source: ESI.
  • the compound of the present invention selectively inhibits the inhibitory ability of estrogen receptor activity and the anti-proliferation activity of the human breast cancer cell line MCF-7 cell line of estrogen receptor wild type, Y537S and D538G mutants, and the biological Activity evaluation can be demonstrated by testing in the following experiments.
  • This experiment is based on the principle of nuclear receptor (NR) agonist-dependent coactivator peptide recruitment response: Tb is labeled on NR through antigen-antibody reaction, and the combination of Agonist and NR leads to a change in its conformation, which in turn leads to a change in the affinity between NR and coactivator peptide. Increase.
  • the proximity of the coactivator peptide (FITC) to NR (Tb) generates a FRET signal.
  • the inhibitory activity of the compounds of the present application on ER ⁇ protein was evaluated based on the above reactions.
  • Test compounds have inhibitory activity on ER ⁇ protein (IC 50 )
  • activity less than *** indicates ⁇ 10nM; ** indicates greater than >10nM, ⁇ 100nM; * indicates >100nM.
  • CCK8 was used to evaluate the anti-proliferative activity of test compounds against human breast cancer cell line MCF-7-ER ⁇ (WT, Y537S, D538G) point mutation stably transformed monoclonal cell line.
  • the above normal growing cells were taken, digested with trypsin cell digestion solution, centrifuged, counted, and plated in a 96-well plate at a cell density of 5000/well, 100 ⁇ L per well.
  • the drug was administered the next day after the cells were plated, and compounds with different concentration gradients were added to each well, and three replicate wells were set up at each concentration point, and a corresponding DMSO negative treatment control group was also set up.
  • ND in the above list means not tested; activity less than *** means ⁇ 10nM; ** means greater than >10nM, ⁇ 100nM; * means >100nM.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，所述式(Ⅰ)化合物的结构为：所述化合物具有很好的选择性抑制雌激素受体活性的抑制能力和对雌激素受体野生型、Y537S及D538G突变体的人乳腺癌细胞株MCF-7细胞株的抗增殖活性，所提供的化合物能够用于预防和/或治疗雌激素受体介导的或依赖性的疾病和病症。

Description

一类苯并七元环类化合物及其应用 技术领域
本发明属于医药领域，涉及一种苯并七元环类化合物及其制备方法和应用，本发明公开了其作为雌激素失败后调节剂预防和/或治疗雌激素受体介导的或依赖性的疾病和病症的用途。
背景技术
在新诊断的女性癌症中，乳腺癌是发病率最高的癌种。而在所有新诊断的乳腺癌中，雌激素受体阳性(ER+)分群病人占75％左右。由于雌激素受体在这部分病人肿瘤中的重要作用，目前主要的治疗都是针对这条信号通路进行，包括使用芳香酶抑制剂如依西美坦、来曲唑、阿那曲唑抑制雌激素合成，使用雌激素受体调节剂(SERM)如他莫西芬或降解剂(SERD)氟维司群直接抑制雌激素受体功能。
在临床上这些疗法的耐药仍然是一个主要的问题。目前的研究发现了很多耐药机制，包括：其他激酶及相关信号通路的激活，尤其是HER2；细胞周期相关信号通路的失调；ER共激活因子异常表达；以及ER蛋白自身的突变。在大约30％对内分泌疗法耐药的病人中都发现了ER的热点突变。这些突变会导致不依赖于配体的受体持续激活，导致对现有疗法的耐药。
带有ER热点突变的病人预后明显差于野生型ER。然而，即使是在针对雌激素受体的多线标准疗法失败耐药后，这部分肿瘤仍然依赖于雌激素受体的功能。所以，开发基于新作用机制的雌激素受体相关信号通路疗法仍然很有必要。
在小分子靶向抗肿瘤药物开发的过程中，非可逆抑制剂是解决耐药的一种重要思路。一个比较经典的例子是EGFR受体不可逆抑制剂阿法替尼的开发(2013年上市)，其结构中的亲电活性基团丙烯酰胺与EGFR受体活性位点中的半胱氨酸残基(巯基)形成共价键，克服了第一代EGFR(吉非替尼、厄洛替尼等)受体抑制剂出现的耐药性问题，同时对非耐药性EGFR受体也表现出良好的活性。非可逆抑制思路同样有希望用于耐药ER+病人的药物开发。
发明内容
发明要解决的问题
为了解决上述问题，本发明提供了一类能够预防和/或治疗雌激素受体介导的或依赖性的疾病和病症的苯并七元环类化合物。
用于解决问题的方案
为了解决上述技术问题，本发明提供了一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，所述式(Ⅰ)化合物的结构为：
Figure PCTCN2022104551-appb-000001
其中，
每一个R 1独立地选自-H,D,-OH,-NH 2,-COOH,-CH 2NH 2和-CH 2OH；
R 2选自取代或未取代的芳基、杂环基和杂芳基；
R 3选自-(CH 2) pCH＝CHCONR 4R 5和-COCH＝CR 6R 7，其中，
R 4，R 5，R 6，R 7分别独立地选自-H、D、烷基、环烷基和杂环基；
或R 4与R 5以及相连的氮原子形成3-7元杂环基，或R 6和R 7以及相连的碳原子形成C 3-6环烷基或3-7元杂环基；
p选自0,1,2和3；
Z选自O、S，CHR 11和NH，R 11可以为H，OH，D,NH 2和C 1-3烷基；
Y选自-R 8NH-、-(CR 9R 10) q NH-和3-7元含氮杂环基，其中，
R 8为C 3-6环烷基或3-7元杂环基；
每一个R 9和R 10分别独立地选自-H、卤素原子、取代或未取代的C 1-6烷基和C 3-6环烷基；或R 9和R 10以及与其相连的碳原子形成取代或未取代的C 3-6环烷基或3-7元杂环基；或R 9或R 10、与R 9或R 10的碳原子以及与所述碳原子相邻的碳原子形成C 3-6环烷基；
q选自1,2,3,4和5；
Figure PCTCN2022104551-appb-000002
选自取代或未取代的芳基和杂芳基；
m选自1,2,3和4。
优选的，R 2选自取代或未取代的苯基、3-9元杂环基和5-10元杂芳基，所述取代是被选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨 基、C 3-6环烷基、C 6-10芳基、5-10元杂芳基或3-7元杂环基中的一个或多个取代基所取代，上述取代基任选被1-3个选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基所取代。更优选的，所述3-9元杂环基选自氮丙啶基、氮杂环丁基、氧杂环丁基、吡咯烷基、四氢呋喃基、四氢噻吩基、哌啶基、吗啉基、哌嗪基、硫代吗啉基、四氢吡喃基、1,1-二氧硫代吗啉基、丁内酰胺基、戊内酰胺基、己内酰胺基、丁内酯基、戊内酯基、己内酯基、2,3-二氢-1H-吲哚基和苯并二氧戊环基中的任一种；
所述5-10元杂芳基含有1-3个任选自N、NH、O、S的杂原子；优选的，所述5-10元杂芳环选自噻吩基、吡啶基、嘧啶基、吡嗪基、哒嗪基、吡咯基、吡唑基、噻唑基、1，2，3-三唑基、1，2，4-三唑基、咪唑基、四氮唑基、异噻唑基、噁唑基、异噁唑基、噻二唑基、噁二唑基、苯并噻吩基、吲哚基、苯并咪唑基、苯并噻唑基、苯并吡唑、苯并呋喃基、苯并恶唑基、苯并异噁唑基、喹啉基、异喹啉基、喹唑啉基、吲唑基或吲哚[1,2-a]吡嗪基中的任一种。
优选的，R 3选自-(CH 2) pCH＝CHCONR 4R 5和-COCH＝CR 6R 7，其中，
R 4，R 5，R 6，R 7分别独立地选自-H、D、C 1-3烷基、C 3-6环烷基和5-6元杂环基；
或R 4与R 5以及相连的氮原子形成5-6元杂环基；
p为1。
优选的，Y选自-R 8NH-、-(CR 9R 10) q NH-和4-6元含氮杂环基，其中，
R 8为C 3-6环烷基或4-6元杂环基；
每一个R 9和R 10分别独立地选自-H、卤素原子、取代或未取代的C 1-6烷基和C 3-6环烷基；或R 9和R 10以及与其相连的碳原子形成C 3-6环烷基或3-7元杂环基；或R 9或R 10、与R 9或R 10的碳原子以及与所述碳原子相邻的碳原子形成C 3-6环烷基；所述取代的C 1-6烷基和C 3-6环烷基是被选自卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基和C 1-6烷氨基的取代基所取代；
q选自1,2和3，优选为2。
优选的，
Figure PCTCN2022104551-appb-000003
选自取代或未取代的C 6-10芳基和5-10元杂芳基，所述取代是被选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基、C 6-10芳基、5-10元杂芳基或3-7元杂环基中的一个或多个取代基所取代，上述取代基任选被1-3个选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基所取代。更优选的，上述
Figure PCTCN2022104551-appb-000004
选自取代或未取代的苯基和 吡啶基，所述取代是被选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基、C 6-10芳基、5-10元杂芳基或3-7元杂环基中的一个或多个取代基所取代，上述取代基任选被1-3个选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基所取代。
优选的，所述化合物的结构如式Ⅱ所示：
Figure PCTCN2022104551-appb-000005
R 1独立地选自-H,-OH和-NH 2；
R 2选自取代或未取代的苯基、C 5-10杂芳基；所述取代是被选自卤素、氰基、C 1-3烷氧基、卤素取代的C 1-3烷氧基的取代基所取代；
R 3选自-CH 2CH＝CHCONR 4R 5，其中，
R 4，R 5分别独立地选自-H和C 1-3烷基；或R 4与R 5以及相连的氮原子形成吡咯烷基或哌啶基；
Z选自O、S和NH；
Y选自-R 8NH-、-(CR 9R 10) q NH-和3-7元含氮杂环基，其中，
R 8为C 3-6环烷基；
每一个R 9和R 10分别独立地选自-H、卤素原子、C 1-3烷基；或R 9和R 10以及与其相连的碳原子形成C 3-6环烷基；
q为2；
Figure PCTCN2022104551-appb-000006
选自取代或未取代的苯基和吡啶基，所述取代是被选自-H、卤素原子和C 1-3烷氧基的取代基所取代。
本发明还提供了一种化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，其特征在于，所述化合物选自：
Figure PCTCN2022104551-appb-000007
Figure PCTCN2022104551-appb-000008
Figure PCTCN2022104551-appb-000009
Figure PCTCN2022104551-appb-000010
本发明还提供了一种药物组合物，其包含上述任一所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物。
本发明还提供了上述任一所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，或者所述的药物组合物，其用作预防和/或治疗雌激素受体介导的或依赖性的疾病和病症。
本发明还提供了上述任一所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，或者所述的药物组合物用作预防和/或治疗雌激素受体介导的或依赖性的疾病和病症的用途。
本发明还提供了上述任一所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，或者所述的药物组合物在制备预防和/或治疗雌激素受体介导的或依赖性的疾病和病症的药物中的应用，优选的，所述疾病为乳腺癌。
本发明还提供了一种预防和/或治疗雌激素受体介导的或依赖性的疾病和病症的方法，其包括下列步骤：将治疗有效量的根据上述任一所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，或者所述的药物组合物施用于对其有需求的患者。
本发明还提供了一种药物联合形式，其包含上述任一所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，或者所述的药物组合物，以及至少一种额外的治疗剂。
发明的效果
本发明所提供的一类苯并七元环类化合物具有很好的选择性抑制雌激素受体活性的抑制能力和对雌激素受体野生型、Y537S及D538G突变体的人乳腺癌细胞株MCF-7细胞株的抗增殖活性，本发明所提供的化合物能够用于预防和/或治疗雌激素受体介导的或依赖性的疾病和病症。
具体实施方式
为使本发明的技术方案和有益效果能够更加明显易懂，下面通过列举具体实施例的方式进行详细说明。
首先，本发明提供了一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，所述式(Ⅰ)化合物的结构为：
Figure PCTCN2022104551-appb-000011
其中，
每一个R 1独立地选自-H,D,-OH,-NH 2,-COOH,-CH 2NH 2和-CH 2OH；
R 2选自取代或未取代的芳基、杂环基和杂芳基；
R 3选自-(CH 2) pCH＝CHCONR 4R 5和-COCH＝CR 6R 7，其中，
R 4，R 5，R 6，R 7分别独立地选自-H、D、烷基、环烷基和杂环基；
或R 4与R 5以及相连的氮原子形成3-7元杂环基，或R 6和R 7以及相连的碳原子形成C 3-6环烷基或3-7元杂环基；
p选自0,1,2和3；
Z选自O、S，CHR 11和NH，R 11可以为H，OH，D,NH 2和C 1-3烷基；
Y选自-R 8NH-、-(CR 9R 10) q NH-和3-7元含氮杂环基，其中，
R 8为C 3-6环烷基或3-7元杂环基；
每一个R 9和R 10分别独立地选自-H、卤素原子、取代或未取代的C 1-6烷基和C 3-6环烷基；或R 9和R 10以及与其相连的碳原子形成取代或未取代的C 3-6环烷基或3-7元杂环基；或R 9或R 10、与R 9或R 10的碳原子以及与所述碳原子相邻的碳原子形成C 3-6环烷基；
q选自1,2,3,4和5；
Figure PCTCN2022104551-appb-000012
选自取代或未取代的芳基和杂芳基；
m选自1,2,3和4。
在一项优选的实施方式中，R 2选自取代或未取代的苯基、3-9元杂环基和5-10元杂芳基，所述取代是被选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基、C 6-10芳基、5-10元杂芳基或3-7元杂环基中的一个或多个取代基所取代，上述取代基任选被1-3个选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基所取代。
在一项更优选的实施方式中，所述3-9元杂环基选自氮丙啶基、氮杂环丁基、氧杂环丁基、吡咯烷基、四氢呋喃基、四氢噻吩基、哌啶基、吗啉基、哌嗪基、硫代吗啉基、四氢吡喃基、1,1-二氧硫代吗啉基、丁内酰胺基、戊内酰胺基、己内酰胺基、丁内酯基、戊内酯基、己内酯基、2,3-二氢-1H-吲哚基和苯并二氧戊环基中的任一种；
所述5-10元杂芳基含有1-3个任选自N、NH、O、S的杂原子；优选的，所述5-10元杂芳环选自噻吩基、吡啶基、嘧啶基、吡嗪基、哒嗪基、吡咯基、吡唑基、噻唑基、1，2，3-三唑基、1，2，4-三唑基、咪唑基、四氮唑基、异噻唑基、噁唑基、异噁唑基、噻二唑基、噁二唑基、苯并噻吩基、吲哚基、苯并咪唑基、苯并噻唑基、苯并吡唑、苯并呋喃基、苯并恶唑基、苯并异噁唑基、喹啉基、异喹啉基、喹唑啉基、吲唑基或吲哚[1,2-a]吡嗪基中的任一种。
在一项优选的实施方式中，R 3选自-(CH 2) pCH＝CHCONR 4R 5和-COCH＝CR 6R 7，其中，
R 4，R 5，R 6，R 7分别独立地选自-H、D、C 1-3烷基、C 3-6环烷基和5-6元杂环基；
或R 4与R 5以及相连的氮原子形成5-6元杂环基；
p为1。
在一项优选的实施方式中，Y选自-R 8NH-、-(CR 9R 10) q NH-和4-6元含氮杂环基，其中，
R 8为C 3-6环烷基或4-6元杂环基；
每一个R 9和R 10分别独立地选自-H、卤素原子、取代或未取代的C 1-6烷基和C 3-6环烷基；或R 9和R 10以及与其相连的碳原子形成C 3-6环烷基或3-7元杂环基；或R 9或R 10、与R 9或R 10的碳原子以及与所述碳原子相邻的碳原子形成C 3-6环烷基；所述取代的C 1-6烷基和C 3-6环烷基是被选自卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基和C 1-6烷氨基的取代基所取代；
q选自1,2和3，优选为2。
在一项优选的实施方式中，
Figure PCTCN2022104551-appb-000013
选自取代或未取代的C 6-10芳基和5-10元杂芳基，所述取代是被选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基、C 6-10芳基、5-10元杂芳基或3-7元杂环基中的一个或多个取代基所 取代，上述取代基任选被1-3个选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基所取代。
在一项更优选的实施方式中，上述
Figure PCTCN2022104551-appb-000014
选自取代或未取代的苯基和吡啶基，所述取代是被选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基、C 6-10芳基、5-10元杂芳基或3-7元杂环基中的一个或多个取代基所取代，上述取代基任选被1-3个选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基所取代。
在一项优选的实施方式中，所述化合物的结构如式Ⅱ所示：
Figure PCTCN2022104551-appb-000015
R 1独立地选自-H,-OH和-NH 2；
R 2选自取代或未取代的苯基、C 5-10杂芳基；所述取代是被选自卤素、氰基、C 1-3烷氧基、卤素取代的C 1-3烷氧基的取代基所取代；
R 3选自-CH 2CH＝CHCONR 4R 5，其中，
R 4，R 5分别独立地选自-H和C 1-3烷基；或R 4与R 5以及相连的氮原子形成吡咯烷基或哌啶基；
Z选自O、S和NH；
Y选自-R 8NH-、-(CR 9R 10) q NH-和3-7元含氮杂环基，其中，
R 8为C 3-6环烷基；
每一个R 9和R 10分别独立地选自-H、卤素原子、C 1-3烷基；或R 9和R 10以及与其相连的碳原子形成C 3-6环烷基；
q为2；
Figure PCTCN2022104551-appb-000016
选自取代或未取代的苯基和吡啶基，所述取代是被选自-H、卤素原子和C 1-3烷氧基的取代基所取代。
本发明还提供了一种化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，其特征在于，所述化合物选自：
Figure PCTCN2022104551-appb-000017
Figure PCTCN2022104551-appb-000018
Figure PCTCN2022104551-appb-000019
Figure PCTCN2022104551-appb-000020
本发明还提供了一种药物组合物，其包含上述任一所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物。
本发明还提供了上述任一所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，或者所述的药物组合物，其用作预防和/或治疗雌激素受体介导的或依赖性的疾病和病症。
本发明还提供了上述任一所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，或者所述的药物组合物用作预防和/或治疗雌激素受体介导的或依赖性的疾病和病症的用途。
本发明还提供了上述任一所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，或者所述的药物组合物在制备预防和/或治疗雌激素受体介导的或依赖性的疾病和病症的药物中的应用。
本发明还提供了一种预防和/或治疗雌激素受体介导的或依赖性的疾病和病症的方法，其包括下列步骤：将治疗有效量的根据上述任一所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，或者所述的药物组合物施用于对其有需求的患者。
最后，本发明还提供了一种药物联合形式，其包含上述任一所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，或者所述的药物组合物，以及至少一种额外的治疗剂。
为了更为清晰地描述本发明的内容，现将所涉及的全部术语定义如下：
术语“卤素原子”指单独或者以组合方式表示氟、氯、溴或碘，特别的是氟、氯或溴。
术语“C 1-6烷基”单独或者以组合方式表示包含1-6个碳原子的饱和直链或支链的烷基，包括甲基、乙基、丙基、异丙基、丁基、仲丁基、异丁基、叔丁基、正戊基、2-戊基、3-戊基、2-甲基-2-丁基、3-甲基-2-丁基、3-甲基-1-丁基、2-甲基-1-丁基、正己基、2-己基、3-己基、2-甲基-2-戊基、3-甲基-2-戊基、4-甲基-2-戊基、3-甲基-3-戊基、2-甲基-3-戊基、 2,3-二甲基-2-丁基、3,3,-二甲基-2-丁基等。优选地，“C 1-6烷基”是甲基、乙基、正丙基、异丙基、叔丁基中的任一种。类似的，术语“C 1-3烷基”单独或者以组合方式表示包含1-3个碳原子的饱和直链或支链的烷基，包括甲基、乙基、正丙基、异丙基等。
术语“C 1-6烷氧基”单独或者以组合方式表示基团C 1-6烷基-O-，其中“C 1-6烷基”表示如以上所定义，其包括(但不限于)甲氧基(-OCH 3)、乙氧基(-OCH 2CH 3)、正丙氧基(-OCH 2CH 2CH 3)、异丙氧基(-OCH(CH 3) 2)、正丁氧基(-OCH 2CH 2CH 2CH 3)、仲丁氧基(-OCH(CH 3)CH 2CH 3)、异丁氧基(-OCH 2CH(CH 3) 2)、叔丁氧基(-OC(CH 3) 3)、正戊氧基(-OCH 2CH 2CH 2CH 2CH 3)、新戊氧基(-OCH 2C(CH 3) 3)等。
术语“C 3-6环烷基”指单独或者以组合方式表示具有3到6个碳原子的饱和或者部分不饱和单环或多环环烷基，包括环丙基、环丁基、环戊基、环己基、环庚基等。
术语“杂环基”表示环上的碳原子被至少一个选自硫、氧或氮的杂原子置换形成的饱和或部分不饱和单环或多环杂环基，术语“3-9元杂环基”是指包含3-9个，特别是3-7个碳原子和杂原子或杂原子基团的饱和或部分不饱和单环或多环杂环基，所述杂原子或杂原子基团选自N、NH、O、C(O)、S(O) m(其中m是0、1或2)；所述3-9元杂环基包括氮丙啶基、氮杂环丁基、氧杂环丁基、吡咯烷基、四氢呋喃基、四氢噻吩基、哌啶基、吗啉基、哌嗪基、硫代吗啉基、四氢吡喃基、1,1-二氧硫代吗啉基、丁内酰胺基、戊内酰胺基、己内酰胺基、丁内酯基、戊内酯基、己内酯基或2,3-二氢-1H-吲哚基和苯并二氧戊环基等中的任一种。术语“3-9元杂环基”和术语“3-9元杂环基”的定义类似，是指包含5-6个碳原子和杂原子或杂原子基团的饱和或部分不饱和单环或多环杂环基
术语“芳基”表示任何稳定的6-10元单环或双环芳香族基团，包括苯基、萘基、四氢萘基、2,3-二氢化茚基或联苯基等。“芳基”上的氢原子独立任选地被一个或多个本发明所描述的取代基所取代。
术语“杂芳基”表示环上的碳原子被至少一个选自硫、氧或氮的杂原子置换形成的芳香环基团，此芳香环基团可以是5-7元单环或7-12双环基团。在本发明中，杂芳基中杂原子个数优选1、2、3或4，例如所述5-10元杂芳环选自噻吩基、吡啶基、嘧啶基、吡嗪基、哒嗪基、吡咯基、吡唑基、噻唑基、1，2，3-三唑基、1，2，4-三唑基、咪唑基、四氮唑基、异噻唑基、噁唑基、异噁唑基、噻二唑基、噁二唑基、苯并噻吩基、苯并吡唑、吲哚基、苯并咪唑基、苯并噻唑基、苯并呋喃基、苯并噁唑基、苯并异噁唑基、喹啉基、异喹啉基、喹唑啉基、吲唑基或吲哚[1,2-a]吡嗪基等中的任一种。“杂芳基”上的氢原子独立任选地被一个或多个本发明所描述的取代基所取代。
术语“C 6-10芳基”表示具有6-10个碳原子的芳基，其中芳基表示如以上所定义。
术语“5-10元杂芳基”表述具有5-10个碳原子和杂原子的杂芳环，其中杂芳环表示如以上所定义。
术语“氨基”单独或者以组合方式表示伯氨基(-NH 2)，仲氨基(-NH-)或叔氨基
Figure PCTCN2022104551-appb-000021
术语“C 1-6烷氨基”单独或者以组合方式表示如上所定义的氨基基团，其中氨基基团的氢原子被至少一个C 1-6烷基所取代，其中“C 1-6烷基”表示如以上所定义，相应地，“C 1-6烷氨基”包括甲基氨基、乙基胺基、丙基氨基、异丙基氨基、正丁基胺基、异丁基氨基、2-丁基氨基、叔丁基氨基、正戊基氨基、2-戊基氨基、3-戊基氨基、2-甲基-2-丁基氨基、3-甲基-2-丁基氨基、3-甲基-1-丁基氨基、2-甲基-1-丁基氨基、正己基氨基、2-己基氨基、3-己基氨基、2-甲基-2-戊基氨基、3-甲基-2-戊基氨基、4-甲基-2-戊基氨基、3-甲基-3-戊基氨基、2-甲基-3-戊基氨基、2,3-二甲基-2-丁基氨基、3,3-二甲基-2-丁基氨基等。特别的“C 1-C 10烷氨基”是甲基氨基、乙基氨基、异丙基氨基、叔丁基氨基等。
术语“异构体”包含所有的同分异构形式包括对映异构体、非对映异构体、互变异构体和几何异构体(包括顺反异构体)。因此，本发明中所设计的化合物的单个立体化学异构体或其对映异构体、非对映异构体、互变异构体或几何异构体(或顺反异构体)的混合物都属于本发明的范围。
术语“药学上可接受的盐”表示本发明的化合物以它们的药用盐的形式存在，包括酸加成盐和碱加成盐。药学上可接受的盐在S.M.Berge在J.Pharmaceutical Sciences(66卷:1-19页,1977年)中描述的pharmaceutically salts中有所描述。在本发明中，药学上可接受的无毒的酸加成盐表示本发明中的化合物与有机或无机酸形成的盐，有机或无机酸包括但不限于盐酸、硫酸、氢溴酸、氢碘酸、磷酸、硝酸、高氯酸、乙酸、草酸、马来酸、富马酸、酒石酸、苯磺酸、甲磺酸、水杨酸、琥珀酸、柠檬酸、乳酸、丙酸、苯甲酸、对甲苯磺酸、苹果酸等。药学上可接受的无毒的碱加成盐表示本发明中的化合物与有机或无机碱所形成的盐，包括但不限于碱金属盐，例如锂、钠或钾盐；碱土金属盐，例如钙或镁盐；有机碱盐，例如通过与含N基团的有机碱形成的铵盐或N +(C 1-6烷基) 4盐，优选为氢氧化锂、氢氧化钠、氢氧化钾、碳酸钠、碳酸氢钠、碳酸钾、碳酸氢钾、碳酸镁、碳酸钙、氨水、三乙胺、四丁基氢氧化铵等。
术语“溶剂化物”表示一个或多个溶剂分子与本发明中的化合物所形成的缔合物。形成溶剂化物的溶剂包括但不限于水、甲醇、乙醇、异丙醇、乙酸乙酯、四氢呋喃、N,N-二甲基甲酰胺、二甲亚砜等。“药学上可接受的盐”可通过一般的化学方法合成。
术语“酯”用于表示有机酯，包括单酯、二酯、三酯、和更通常地多酯。
术语“前药”表示作为本发明的化合物的化学衍生物，该衍生物在体内通过发生化学反应转换成通式I所表示的化合物。
术语“同位素衍生物”表示通式(I)中的氢原子被1-6个氘原子(D)所取代得到的同位素衍生物、通式(I)中的碳原子被1-3个碳14原子( 14C)所取代得到的同位素衍生物。
以上对本发明的涉及的术语进行了定义，本领域技术人员还可以结合现有技术对以上术语进行理解，以下基于本发明的内容以及对术语的定义进一步进行描述。
下面的实施例可以对本发明做进一步的描述，然而，这些实施例不应作为对本发明的范围的限制。
实施例1化合物001的制备
Figure PCTCN2022104551-appb-000022
化合物001的制备路线如下：
Figure PCTCN2022104551-appb-000023
Figure PCTCN2022104551-appb-000024
向化合物001-1(15.0g,68.2mmol,1.0eq.)的CH 3CN(150mL)溶液中一次加入Cs 2CO 3(44.4g,136.3mmol,2.0eq.)和化合物001-2(21.4g,95.4mmol,1.4eq.)，该反应混合物在110℃下反应16小时。待反应完成后，将反应混合物倒入300mL水中，乙酸乙酯萃取三次(450mL)，合并有机相，硫酸镁干燥，浓缩、柱层析得到黄色油状化合物001-3(21.8g,49.8mmol,73.1％)。 1H NMR:(400MHz,DMSO-d 6)δ7.60(d,J＝8.6Hz,2H),7.51(d,J＝8.4Hz,1H),6.92(d,J＝8.5Hz,2H),3.98(t,J＝5.8Hz,2H),3.32-3.24(m,2H),1.40-1.37(m,9H),1.30-1.26(m,12H)。
Figure PCTCN2022104551-appb-000025
在氮气保护的条件下，向冷却至0℃的001-4(5.0g,30.3mmol,1.0eq.)的无水四氢呋喃(100mL)溶液中加入SOCl2(14.4g,121.2mmol,8.79mL,4.0eq.)，反应混合物移至室温继续反应12小时，浓缩得到棕色油状化合物，直接用于后续反应。将上述棕色油状化合物溶解于50mL无水二氯甲烷中，在氮气保护条件下一次加入二甲胺盐酸盐hydrochloride(2.45g,30.0mmol,1.1eq.)，三乙胺的二氯甲烷溶液(8.27g溶解于100mL二氯甲烷,3.0eq.)。室温反应完成后，向反应混合物中加入100mL水，分液得到有机相，水相再以二氯甲烷萃取两次，合并有机相并以硫酸镁干燥，浓缩得到棕色油状物，直接用于下一步反应。
1H NMR:(400MHz,DMSO-d6)δ6.93-6.77(m,1H),6.55-6.37(m,1H),4.16-3.95(m,2H),3.04-2.93(m,6H)。(ESI+)m/z 192.0(M+H) +。
Figure PCTCN2022104551-appb-000026
向化合物001-6(45.0g,236.6mmol,1.0eq.)的无水甲苯(500mL)溶液中缓慢加入AlCl3(75.7g,567.7mmol,31.0mL,2.4eq.)，反应混合物在90℃下反应一小时。反应化合物倒入1500mL的冰水混合物中，悬浊液搅拌20分钟，过滤得到固体物质，并用500mL水洗滤饼，减压浓缩得到黄色固体物质001-7(41.0g,232.7mmol,98.4％)。
1H NMR:(400MHz,DMSO-d 6)δ10.13(s,1H),7.55(d,J＝8.5Hz,1H),6.70(dd,J＝2.4,8.4 Hz,1H),6.65(d,J＝2.3Hz,1H),2.89-2.79(m,2H),2.65-2.57(m,2H),1.80-1.71(m,2H),1.71-1.62(m,2H)。
Figure PCTCN2022104551-appb-000027
向化合物001-7(41.0g,232.7mmol,1.0eq.)的丙酮(500mL)溶液中一次加入碳酸钾(32.2g,232.7mmol,1.0eq.),2,2-二甲基丙酸酰氯(32.3g,267.6mmol,32.9mL,1.15eq.)，室温反应16小时。将反应混合物减压浓缩，并向其中加入500mL水和500mL乙酸乙酯，饱和食盐水洗有机相，并以硫酸镁干燥有机相，浓缩得到的粗产物进行柱层析得到黄色固体化合物001-8(52.0g,199.8mmol,85.9％)。
1H NMR:(400MHz,DMSO-d 6)7.68-7.75(m,1H),7.27-6.88(m,2H),2.95(t,J＝6.4Hz,2H),2.69(t,J＝6.4Hz,2H),1.83-1.76(m,2H),1.75-1.66(m,2H),1.31(s,9H).
Figure PCTCN2022104551-appb-000028
在室温下，向化合物001-8(22.5g,86.4mmol,1.0eq.)和吡啶(10.3g,129.6mmol,10.5mL,1.5eq.)的二氯甲烷溶液中(500mL)滴加三氟甲磺酸酐(48.8g,172.9mmol,28.5mL,2.0eq.)反应混合物继续在室温反应2个小时。向反应混合物中缓慢滴加250mL水，分离有机相。以饱和食盐水洗有机相一次，并用硫酸镁干燥。浓缩得到的粗产物进行柱层析分离，得到白色固体化合物001-9(31.5g,80.3mmol,92.9％)
1H NMR:(400MHz,DMSO-d 6)δ7.50(d,J＝9.3Hz,1H),7.13(dd,J＝2.3,4.5Hz,2H),6.40(t,J＝6.1Hz,1H),2.85-2.62(m,2H),2.33-2.17(m,2H),2.08-1.86(m,2H),1.31(s,9H)。
Figure PCTCN2022104551-appb-000029
将化合物001-9(13.0g,33.1mmol,1.0eq.)和001-3(12.6g,34.8mmol,1.05eq.)溶解于二氧六环(130mL)和水(25mL)中，并向该溶液中一次加入Pd(dppf)Cl 2(1.21g,1.66mmol, 0.05eq.)和碳酸铯(21.6g,66.3mmol,2.0eq.)，该反应混合物在室温反应一小时。缓慢地向反应混合物中加入饱和食盐水(100mL)和二氯甲烷(100mL)，分离有机相，并以硫酸镁干燥。浓缩得到的粗产物经过柱层析纯化得到白色固体产物001-10(14.8g,30.9mmol,93.1％)。
1H NMR:(400MHz,DMSO-d 6)7.13(d,J＝8.8Hz,2H),7.09-7.06(m,1H),7.03-6.98(m,1H),6.95-6.88(m,4H),6.38(t,J＝7.3Hz,1H),3.96(brt,J＝5.8Hz,2H),3.31-3.26(m,2H),2.62-2.56(m,2H),2.17-2.08(m,2H),1.88(q,J＝7.4Hz,2H),1.39(s,9H),1.32(s,9H).
Figure PCTCN2022104551-appb-000030
在室温条件下，向化合物001-10(14.8g,30.9mmol,1.0eq.)的四氢呋喃(200mL)溶液中加入三溴吡啶盐(10.4g,32.4mmol,1.05eq.)，该反应混合液在室温下继续反应一小时。将反应混合物加入到饱和碳酸氢钠(100mL)溶液中，以二氯甲烷(100mL*2)萃取上述混合物，合并有机相，并以饱和食盐水洗涤有机相，硫酸镁干燥有机相。浓缩得到的粗产物经过柱层析得到白色固体产物001-11(11.5g,20.6mmol,66.7％)。
1H NMR:(400MHz,DMSO-d 6)δ7.14(d,J＝8.8Hz,2H),7.11-7.08(m,1H),7.07-7.01(m,1H),6.98-6.91(m,3H),6.83-6.76(m,2H),4.00(br t,J＝5.8Hz,2H),3.66-3.61(m,1H),2.81-2.73(m,2H),2.28(br t,J＝6.9Hz,2H),1.80(td,J＝3.2,6.7Hz,1H),1.42(s,9H),1.33(s,10H).
Figure PCTCN2022104551-appb-000031
将化合物001-11(198.5mg,1.29mmol,1.2eq.)、(0.6g,1.07mmol,1.0eq.)和Cs 2CO 3(700.0mg,2.15mmol,2.0eq.)溶于二氧六环(5mL)和水(1mL)中，反应混合脱气并以氮气保护，向上述反应混合物中加入Pd(dppf)Cl 2(39.3mg,53.7umol,0.05eq.)，该反应混合物继续在90℃下反应一小时。反应混合物以H 2O(100mL)稀释，并用乙酸乙酯萃取两次(100mL*2)。饱和食盐水洗涤有机相、硫酸镁干燥，浓缩得到的粗产物经过柱色谱纯化得到黄色油状物 001-12(750mg,1.02mmol,95.0％)
1H NMR:(400MHz,CDCl 3)δ6.96-6.85(m,2H),6.80-6.69(m,6H),6.57-6.44(m,2H),4.97-4.78(m,1H),3.85(t,J＝5.0Hz,2H),3.40(d,J＝5.0Hz,2H),2.73(t,J＝6.9Hz,2H),2.26-2.22(m,1H),2.30-2.18(m,4H),2.09(q,J＝6.8Hz,2H),1.37(s,9H),1.29(s,9H)。
Figure PCTCN2022104551-appb-000032
向化合物001-12(500mg,850.8umol,1.0eq.)的二氯甲烷(5mL)溶液中加入三氟乙酸(1.54g,13.5mmol,1.0mL,15.9eq.)，反应化合物在室温下反应两小时。反应也浓缩后得到黄色固体产物001-13(500mg,831.1μmol,97.7％)，直接用于下一步反应。
(ESI+)m/z 488.2(M+H) +。
Figure PCTCN2022104551-appb-000033
向化合物001-13(450mg,922.9μmol,1.0eq.)的N，N-二甲酰胺(20mL)的溶液中以此加入化合物001-05(141.8mg,738.3μmol,0.8eq.),碘化钾(153.2mg,922.9μmol,1.0eq.)和碳酸钾(255.1mg,1.85mmol,2.0eq.)。该反应混合物在室温下反应十六小时。反应混合物用50mL水稀释，乙酸乙酯萃取稀释后的溶液三次(50mL*3)。合并有机相，用硫酸镁干燥，浓缩得到粗产物，柱层析得到黄色油状化合物001-14(76mg,124.4μmol,13.5％)。
(ESI+)m/z 599.5(M+H) +。
Figure PCTCN2022104551-appb-000034
向化合物001-14(76mg,126.9umol,1.0eq.)的甲醇溶液中(1mL)加入氢氧化钠(10.2mg,253.9umol,2.0eq.)，反应混合物反应一小时。以3mol/L盐酸调节反应混合物的pH到6，粗品经过制备液相色谱纯化得到白色固体化合物001(43.74mg,62.6％)。制备液相条件：柱子:Phenomenex Luna C18 100*30mm*3um；流动相:A水(0.225％甲酸)，B乙腈，B％:25％-45％,8分钟。
1H NMR:(400MHz,DMSO-d 6)δ8.19(s,1H),7.01(t,J＝7.9Hz,1H),6.91-6.80(m,2H),6.73(t,J＝9.3Hz,3H),6.69-6.64(m,2H),6.64-6.58(m,1H),6.58-6.50(m,3H),3.93(t,J＝5.5Hz,2H),3.27-3.18(m,2H),3.02(s,3H),2.86(s,3H),2.85-2.81(m,2H),2.72-2.67(m,2H),2.24(s,3H),2.20-2.14(m,2H),2.09-2.02(m,2H)；(ESI+)m/z 515.3(M+H) +。
LCMS条件:流动相:0.02％氨水(流动相A)，乙腈(流动相B),经过三分钟流动相B从10％到80％，保持80％的流动相B0.5分钟，流速：1.0ml/min；色谱柱:Xbrige Shield RP-18,5um,2.1*50mm；检测波长:UV 220nm和254nm；柱温:50℃。
实施例2化合物002的制备
Figure PCTCN2022104551-appb-000035
参照实施例1合成路线合成得到黄色固体化合物002。
1H NMR:(400MHz,DMSO-d 6)δ9.50(s,1H),9.07-8.81(m,2H),7.57(d,J＝2.1Hz,1H),7.26(dd,J＝2.1,8.3Hz,1H),7.20-7.13(m,1H),6.86-6.73(m,6H),6.63-6.53(m,3H),4.13(br t,J＝4.9Hz,2H),3.83(br d,J＝3.0Hz,2H),3.05(s,4H),2.89(s,4H),2.82-2.72(m,2H),2.23-2.14(m,2H),2.13-2.04(m,2H)；(ESI+)m/z 551.0(M+H) +。
液相质谱联用(LC-MS)条件:0.037％三氟乙酸水溶液(流动相A)，0.018％三氟乙酸乙腈溶液(流动相B),流动相B经过3分钟从5％-80％，保持80％流动相B0.5分钟；流速：1mL/min；柱子:
Figure PCTCN2022104551-appb-000036
C18 2.1*30mm,3um；检测波长:UV 220nm和254nm；柱温:50℃；质谱离子源:ESI。
实施例3化合物003的制备
Figure PCTCN2022104551-appb-000037
参照实施例1合成得到白色固体化合物003。
1H NMR:(400MHz,DMSO-d 6)δ10.41-8.77(m,1H),8.20(s,1H),7.38(dd,J＝2.5,8.9Hz,1H),7.17(dd,J＝6.4,8.4Hz,1H),7.04(dt,J＝2.6,8.5Hz,1H),6.78-6.59(m,6H),6.58-6.49(m,3H),3.92(br t,J＝5.5Hz,2H),3.36(br d,J＝4.9Hz,2H),3.02(s,3H),2.90-2.73(m,7H),2.24-2.15(m,2H),2.09(br s,2H)； 19FNMR:(400MHz,DMSO-d 6)δ-114.18(s,1F)；(ESI+)m/z 535.1(M+H) +。
液相质谱联用(LC-MS)条件:0.037％三氟乙酸水溶液(流动相A)，0.018％三氟乙酸乙腈溶液(流动相B),流动相B经过3分钟从5％-80％，保持80％流动相B0.5分钟；流速：1mL/min；柱子:
Figure PCTCN2022104551-appb-000038
C18 2.1*30mm,3um；检测波长:UV 220nm和254nm；柱温:50℃；质谱离子源:ESI。
实施例4化合物004的制备
Figure PCTCN2022104551-appb-000039
参照实施例1合成得到白色固体化合物004。
1H NMR:(400MHz,DMSO-d 6)δ9.40(s,1H),7.18(d,J＝1.8Hz,1H),7.13-6.98(m,2H),6.71(s,1H),6.70-6.63(m,4H),6.63-6.59(m,1H),6.58-6.49(m,3H),3.91(t,J＝5.5Hz,2H),3.30(s,1H),3.01(s,3H),2.86(s,3H),2.80(br t,J＝5.5Hz,2H),2.77-2.66(m,3H),2.14(s,5H),2.07(br dd,J＝5.6,11.9Hz,2H)；(ESI+)m/z 531.3(M+H) +。
LCMS条件:流动相:0.02％氨水(流动相A)，乙腈(流动相B),经过六分钟流动相B从10％到80％，保持80％的流动相B一分钟，流速：1.0ml/min；色谱柱:Xbrige Shield RP-18,5um,2.1*50mm；检测波长:220nm和254nm；柱温:45℃。
实施例5化合物005的制备
Figure PCTCN2022104551-appb-000040
参照实施例1合成得到白色固体化合物005。
1H NMR:(400MHz,DMSO-d 6)δ9.38(s,1H),6.98-6.91(m,1H),6.88(t,J＝7.4Hz,1H),6.82-6.77(m,1H),6.73-6.66(m,3H),6.64-6.58(m,3H),6.58-6.51(m,3H),3.91(br t,J＝5.4 Hz,2H),3.33(br s,2H),3.01(s,3H),2.86(s,3H),2.85-2.81(m,2H),2.81-2.72(m,1H),2.72-2.66(m,1H),2.49-2.40(m,1H),2.19(s,3H),2.15(br d,J＝6.6Hz,1H),2.12(s,3H),2.09-1.98(m,3H)；(ESI+)m/z 511.1(M+H) +。
液相质谱联用(LC-MS)条件:0.037％三氟乙酸水溶液(流动相A)，0.018％三氟乙酸乙腈溶液(流动相B),流动相B经过3分钟从5％-80％，保持80％流动相B0.5分钟；流速：1mL/min；柱子:
Figure PCTCN2022104551-appb-000041
C18 2.1*30mm,3um；检测波长:UV 220nm和254nm；柱温:50℃；质谱离子源:ESI。
实施例6化合物006的制备
Figure PCTCN2022104551-appb-000042
参照实施例1合成得到白色固体化合物006。
1H NMR:(400MHz,DMSO-d 6)δ9.38(s,1H),6.98-6.91(m,1H),6.88(t,J＝7.4Hz,1H),6.82-6.77(m,1H),6.73-6.66(m,3H),6.64-6.58(m,3H),6.58-6.51(m,3H),3.91(br t,J＝5.6Hz,2H),3.92(t,J＝5.6Hz,2H),3.01(s,3H),2.86(s,3H),2.76-2.65(m,4H),2.09-2.07(m,2H),2.06-2.04(m,4H),1.29(t,J＝7.2Hz,3H)；(ESI+)m/z 561.1(M+H) +。
液相质谱联用(LC-MS)条件:0.037％三氟乙酸水溶液(流动相A)，0.018％三氟乙酸乙腈溶液(流动相B),流动相B经过3分钟从5％-80％，保持80％流动相B0.5分钟；流速：1mL/min；柱子:
Figure PCTCN2022104551-appb-000043
C18 2.1*30mm,3um；检测波长:UV 220nm和254nm；柱温:50℃；质谱离子源:ESI。
实施例7化合物007的制备
Figure PCTCN2022104551-appb-000044
参照实施例1合成得到白色固体化合物007。
1H NMR:(400MHz,DMSO-d 6)δ9.85-9.68(m,1H),7.24-7.15(m,3H),7.06-7.00(m,2H),6.74-6.65(m,7H),6.55-6.50(m,1H),3.95-3.91(m,2H),3.06-2.97(m,4H),2.90-2.79(m,6H),2.69-2.52(m,5H)； 19F NMR:(400MHz,DMSO-d 6)δ-82.23(d,J＝3.5Hz,2F),-131.66-131.71(s,1F)；(ESI+)m/z 567.1(M+H) +。
液相质谱联用(LC-MS)条件:0.037％三氟乙酸水溶液(流动相A)，0.018％三氟乙酸乙腈溶液(流动相B),流动相B经过3分钟从5％-80％，保持80％流动相B0.5分钟；流速：1mL/min；柱子:
Figure PCTCN2022104551-appb-000045
C18 2.1*30mm,3um；检测波长:UV 220nm和254nm；柱温:50℃；质谱离子源:ESI。
实施例8化合物008的制备
Figure PCTCN2022104551-appb-000046
参照实施例1合成得到白色固体化合物008。
1H NMR:(400MHz,DMSO-d 6)δ9.82-9.65(m,1H),7.07-6.98(m,2H),6.92-6.86(m,1H), 6.74-6.59(m,8H),6.56-6.49(m,1H),3.96-3.83(m,4H),3.05-2.98(m,3H),2.88-2.79(m,5H),2.70-2.54(m,3H),2.49-2.31(m,4H),1.23-1.18(m,3H)； 19F NMR:(400MHz,DMSO-d 6)δ-137.38(s,1F)；(ESI+)m/z 545.2(M+H) +。
液相质谱联用(LC-MS)条件:0.037％三氟乙酸水溶液(流动相A)，0.018％三氟乙酸乙腈溶液(流动相B),流动相B经过3分钟从5％-80％，保持80％流动相B0.5分钟；流速：1mL/min；柱子:
Figure PCTCN2022104551-appb-000047
C18 2.1*30mm,3um；检测波长:UV 220nm和254nm；柱温:50℃；质谱离子源:ESI。
实施例9化合物009的制备
Figure PCTCN2022104551-appb-000048
参照实施例1合成得到白色固体化合物009。
1H NMR:(400MHz,DMSO-d 6)δ8.19(s,1H),6.97-6.89(m,2H),6.89-6.82(m,1H),6.79-6.74(m,2H),6.71(br d,J＝9.0Hz,3H),6.66-6.59(m,1H),6.58-6.42(m,3H),4.03(q,J＝7.0Hz,2H),3.95(br t,J＝5.5Hz,2H),3.37(br s,2H),3.02(s,3H),2.86(s,3H),2.84(br s,2H),2.67(br d,J＝6.3Hz,2H),2.23(br t,J＝6.5Hz,2H),2.09-1.99(m,2H),1.31(t,J＝6.8Hz,3H).； 19F NMR:(400MHz,DMSO-d 6)δ-135.44(s,1F)；(ESI+)m/z 545.2(M+H) +；
液相质谱联用(LC-MS)条件:0.037％三氟乙酸水溶液(流动相A)，0.018％三氟乙酸乙腈溶液(流动相B),流动相B经过3分钟从5％-80％，保持80％流动相B0.5分钟；流速：1mL/min；柱子:
Figure PCTCN2022104551-appb-000049
C18 2.1*30mm,3um；检测波长:UV 220nm和254nm；柱温:50℃；质谱离子源:ESI。
实施例10化合物010的制备
Figure PCTCN2022104551-appb-000050
参照实施例1合成得到白色固体化合物010。
1H NMR:(400MHz,DMSO-d 6)δ10.10-8.93(m,1H),8.43(d,J＝1.5Hz,1H),8.18(s,1H),7.88-7.82(m,1H),7.74(d,J＝8.1Hz,1H),6.76(br d,J＝13.4Hz,5H),6.58(s,4H),3.99-3.93(m,2H),3.18-3.13(m,2H),3.10-2.98(m,3H),2.89-2.82(m,5H),2.76-2.70(m,2H),2.40-2.29(m,2H),2.13-2.04(m,2H)； 19FNMR:δ-66.11(s,1F)；(ESI+)m/z 552.1(M+H) +；
液相质谱联用(LC-MS)条件:0.037％三氟乙酸水溶液(流动相A)，0.018％三氟乙酸乙腈溶液(流动相B),流动相B经过3分钟从5％-80％，保持80％流动相B0.5分钟；流速：1mL/min；柱子:
Figure PCTCN2022104551-appb-000051
C18 2.1*30mm,3um；检测波长:UV 220nm和254nm；柱温:50℃；质谱离子源:ESI。
实施例11化合物011的制备
Figure PCTCN2022104551-appb-000052
在0摄氏度条件下，缓慢地向化合物011-1(0.8g,4.27mmol,1.0eq.)和三乙胺(864.7mg,8.55mmol,1.19mL,2.0eq.)的二氯甲烷溶液中(30mL)加入甲烷磺酰氯(0.62g,5.41mmol,418.9uL,1.27eq.)，加毕，反应混合液在室温下反应2小时。100mL冰水淬灭反应，分液得到有机相，二氯甲烷萃取水相两次(100mL*2)。合并有机相，并用饱和食盐水洗涤一次，硫酸镁干燥，浓缩得到的粗产物经过柱层析得到白色固体化合物011-2(1.1g,3.32mmol,77.6％)。
1H NMR:(400MHz,CDCl 3)δ4.77-4.70(m,2H),3.84(br s,1H),3.01(s,3H),2.96-2.90(m,2H),2.24-2.18(m,2H),1.46(s,9H)。
Figure PCTCN2022104551-appb-000053
将化合物011-2(2.65g,9.99mmol,1.0eq.)和化合物011-3(2.20g,9.99mmol,1.0eq溶解于N，N-二甲基甲酰胺(80mL)中，向其中加入碳酸钾(2.76g,19.9mmol,2.0eq.)，该反应混合物在90℃反应12小时。加入300mL水稀释反应混合物，并用乙酸乙酯萃取三次(20mL*3)。合并有机相，并以饱和食盐水洗(100mL*2，硫酸镁干燥有机相，浓缩得到的粗产物经过柱层析得到黄色油状化合物011-4(1.9g,4.88mmol,48.9％)。
1H NMR:(400MHz,CDCl 3)δ7.71-7.62(m,2H),6.80-6.65(m,2H),4.80-4.57(m,1H),4.38-4.14(m,1H),2.88(br s,1H),2.53-2.27(m,2H),1.96-1.88(m,2H),1.60-1.32(m,9H),1.26(s,12H)；。
Figure PCTCN2022104551-appb-000054
参照实施例1合成得到白色固体化合物011。
1H NMR:(400MHz,DMSO-d 6)δ9.79-9.17(m,1H),8.17(s,1H),7.55(d,J＝2.1Hz,1H),7.24(dd,J＝2.1,8.3Hz,1H),7.14(d,J＝8.3Hz,1H),6.76-6.69(m,3H),6.67-6.47(m,6H),4.72-4.67(m,1H),4.30-4.25(m,1H),3.40-3.26(m,2H),3.01(s,3H),2.86(s,3H),2.72-2.64(m,2H),2.25-2.01(m,8H).；LCMS：(ESI+)m/z 577.1(M+H) +。
液相质谱联用(LC-MS)条件:0.037％三氟乙酸水溶液(流动相A)，0.018％三氟乙酸乙腈溶液(流动相B),流动相B经过3分钟从5％-80％，保持80％流动相B0.5分钟；流速：1mL/min；柱子:
Figure PCTCN2022104551-appb-000055
C18 2.1*30mm,3um；检测波长:UV 220nm和254nm；柱温:50℃； 质谱离子源:ESI。
实施例12化合物012的制备
Figure PCTCN2022104551-appb-000056
参照实施例1合成得到白色固体化合物012。
1H NMR:(400MHz,DMSO-d 6)δ9.81-8.86(m,1H),8.24(s,1H),7.04(dd,J＝6.3,8.3Hz,1H),6.95(dd,J＝2.4,10.4Hz,1H),6.86(dt,J＝2.8,8.4Hz,1H),6.74-6.59(m,5H),6.58-6.47(m,3H),3.91(t,J＝5.6Hz,2H),3.35-3.34(m,2H),3.01(s,3H),2.86(s,3H),2.82-2.72(m,4H),2.15(s,3H),2.13-2.07(m,4H)；LCMS:(ESI+)m/z 515.3(M+H) +。
LCMS条件:流动相:0.02％氨水(流动相A)，乙腈(流动相B),经过三分钟流动相B从10％到80％，保持80％的流动相B0.5分钟，流速：1.0ml/min；色谱柱:Xbrige Shield RP-18,5um,2.1*50mm；检测波长:UV 220nm和254nm；柱温:50℃。
实施例13化合物013的制备
Figure PCTCN2022104551-appb-000057
参照实施例1合成得到白色固体化合物013。
1H NMR:(400MHz,DMSO-d 6)δ9.44(s,1H),7.97(d,J＝2.1Hz,1H),7.64(s,2H),6.93(d,J＝8.5Hz,1H),6.81-6.70(m,5H),6.56(s,4H),3.95(t,J＝5.5Hz,2H),3.37-3.34(m,2H),3.02(s,3H),2.86(s,5H),2.72-2.67(m,2H),2.36-2.24(m,3H),2.12-2.05(m,2H)； 19F NMR:δ-87.09(s,1F)；LCMS:(ESI+)m/z 550.1(M+H) +。
液相质谱联用(LC-MS)条件:0.037％三氟乙酸水溶液(流动相A)，0.018％三氟乙酸乙腈溶液(流动相B),流动相B经过3分钟从5％-80％，保持80％流动相B0.5分钟；流速：1mL/min；柱子:
Figure PCTCN2022104551-appb-000058
C18 2.1*30mm,3um；检测波长:UV 220nm和254nm；柱温:50℃；质谱离子源:ESI。
实施例14化合物014的制备
Figure PCTCN2022104551-appb-000059
参照实施例11合成得到白色固体化合物014。
1H NMR:(400MHz,DMSO-d 6)δ8.19(s,1H),7.55(d,J＝2.0Hz,1H),7.28-7.20(m,1H),7.14(d,J＝8.4Hz,1H),6.76-6.69(m,3H),6.62(d,J＝8.8Hz,2H),6.60-6.46(m,4H),4.75(t,J＝6.4Hz,1H),3.20(br d,J＝5.0Hz,2H),3.00(s,3H),2.86(s,3H),2.80-2.62(m,4H),2.56(br d,J＝10.4Hz,1H),2.41(br d,J＝7.1Hz,1H),2.22(br s,1H),2.18-2.12(m,2H),2.08(br s,2H),1.71(br dd,J＝5.5,7.9Hz,1H).；(ESI+)m/z 577.2(M+H) +。
液相质谱联用(LC-MS)条件:0.037％三氟乙酸水溶液(流动相A)，0.018％三氟乙酸乙腈溶液(流动相B),流动相B经过3分钟从5％-80％，保持80％流动相B0.5分钟；流速：1mL/min；柱子:
Figure PCTCN2022104551-appb-000060
C18 2.1*30mm,3um；检测波长:UV 220nm和254nm；柱温:50℃；质谱离子源:ESI。
实施例15化合物015的制备
Figure PCTCN2022104551-appb-000061
参照实施例11合成得到白色固体化合物015。
1H NMR:(400MHz,DMSO-d 6)δ8.20(s,1H),7.55(d,J＝2.1Hz,1H),7.30-7.21(m,1H),7.19-7.10(m,1H),6.76-6.66(m,5H),6.66-6.59(m,1H),6.58-6.53(m,2H),6.52-6.45(m,1H),3.82(s,2H),3.42(br s,2H),2.99-2.95(m,3H),2.84(s,3H),2.80-2.70(m,2H),2.22-2.12(m,2H),2.12-1.98(m,2H),0.66-0.57(m,2H),0.57-0.47(m,2H)；LCMS:(ESI+)m/z 577.0(M+H) +。
液相质谱联用(LC-MS)条件:0.037％三氟乙酸水溶液(流动相A)，0.018％三氟乙酸乙腈溶液(流动相B),流动相B经过3分钟从5％-80％，保持80％流动相B0.5分钟；流速：1mL/min；柱子:
Figure PCTCN2022104551-appb-000062
C18 2.1*30mm,3um；检测波长:UV 220nm和254nm；柱温:50℃；质谱离子源:ESI。
实施例16化合物016的制备
Figure PCTCN2022104551-appb-000063
参照实施例11合成得到白色固体化合物016。
1H NMR:(400MHz,DMSO-d 6)δ11.36-11.07(m,1H),9.53(br s,1H),7.57(d,J＝2.1Hz,1H),7.29-7.21(m,1H),7.16(d,J＝8.3Hz,1H),6.96-6.84(m,1H),6.79(d,J＝8.6Hz,2H),6.74(d,J＝2.3Hz,1H),6.67-6.61(m,2H),6.60-6.55(m,1H),6.52-6.43(m,1H),6.52-6.42(m,1H),5.12-4.76(m,1H),4.62(br s,1H),4.39(br s,1H),4.24-3.87(m,4H),3.06(br s,3H),2.88(s,3H),2.82-2.70(m,2H),2.22-2.14(m,2H),2.12-2.02(m,2H)；LCMS：(ESI+)m/z 563.1(M+H) +。
液相质谱联用(LC-MS)条件:0.037％三氟乙酸水溶液(流动相A)，0.018％三氟乙酸乙腈溶液(流动相B),流动相B经过3分钟从5％-80％，保持80％流动相B0.5分钟；流速：1mL/min；柱子:
Figure PCTCN2022104551-appb-000064
C18 2.1*30mm,3um；检测波长:UV 220nm和254nm；柱温:50℃；质谱离子源:ESI。
实施例17化合物017的制备
Figure PCTCN2022104551-appb-000065
参照实施例11合成得到白色固体化合物017。
1H NMR:(400MHz,DMSO-d 6)δ9.52(s,1H),7.55(d,J＝2.0Hz,1H),7.29-7.22(m,1H),7.21-7.15(m,1H),6.82-6.71(m,6H),6.67-6.61(m,2H),6.59-6.49(m,2H),4.10(s,2H),3.93(br d,J＝3.0Hz,2H),3.57-3.47(m,2H),3.35-3.24(m,2H),2.84-2.71(m,2H),2.22-2.14(m,2H),2.13-2.03(m,2H),1.87(q,J＝6.5Hz,2H),1.80(q,J＝6.5Hz,2H),1.28-1.19(m,2H),1.00-0.91(m,2H).；LCMS：(ESI+)m/z 603.1(M+H) +。
液相质谱联用(LC-MS)条件:0.037％三氟乙酸水溶液(流动相A)，0.018％三氟乙酸乙腈溶液(流动相B),流动相B经过3分钟从5％-80％，保持80％流动相B0.5分钟；流速：1mL/min；柱子:
Figure PCTCN2022104551-appb-000066
C18 2.1*30mm,3um；检测波长:UV 220nm和254nm；柱温:50℃；质谱离子源:ESI。
实施例18化合物018的制备
Figure PCTCN2022104551-appb-000067
参照实施例1合成得到白色固体化合物018。
1H NMR:(400MHz,DMSO-d 6)δ9.72-9.44(m,1H),9.35(br s,2H),7.56(d,J＝2.0Hz,1H),7.26(dd,J＝1.9,8.3Hz,1H),7.17(d,J＝8.3Hz,1H),6.86-6.70(m,5H),6.69-6.61(m,2H),6.60-6.52(m,2H),4.18(br t,J＝4.4Hz,2H),3.82(br s,2H),3.51(br t,J＝6.8Hz,2H),3.33(br s,2H),3.28(br s,2H),2.84-2.71(m,2H),2.18(br d,J＝6.4Hz,2H),2.08(br d,J＝5.0Hz,2H),1.94-1.85(m,2H),1.79(td,J＝6.4,13.3Hz,2H)；LCMS：(ESI+)m/z 577.1(M+H) +。
液相质谱联用(LC-MS)条件:0.037％三氟乙酸水溶液(流动相A)，0.018％三氟乙酸乙腈溶液(流动相B),流动相B经过3分钟从5％-80％，保持80％流动相B0.5分钟；流速：1mL/min；柱子:
Figure PCTCN2022104551-appb-000068
C18 2.1*30mm,3um；检测波长:UV 220nm和254nm；柱温:50℃；质谱离子源:ESI。
实施例19化合物030的制备
Figure PCTCN2022104551-appb-000069
参照实施例1合成得到白色固体化合物030。
1H NMR:(400MHz,DMSO-d 6)δ9.40(s,1H),8.65(s,1H),7.55(dd,J＝3.4,4.7Hz,2H),7.19(dd,J＝1.3,8.6Hz,1H),6.77-6.69(m,3H),6.67-6.62(m,2H),6.60(s,1H),6.56(d,J＝ 1.0Hz,2H),6.53-6.47(m,1H),3.89(t,J＝5.5Hz,2H),3.36-3.34(m,2H),3.00(s,3H),2.85(s,3H),2.78(br t,J＝5.0Hz,2H),2.72(brs,2H),2.32(br d,J＝1.8Hz,2H),2.14-1.99(m,3H)；LCMS：(ESI+)m/z 524.6(M+H) +。
实施例20化合物031的制备
Figure PCTCN2022104551-appb-000070
参照实施例1合成得到白色固体化合物031。
1H NMR:(400MHz,DMSO-d 6)δ13.13-12.67(m,1H),9.73-9.07(m,1H),7.93(s,1H),7.53(s,1H),7.34-7.26(m,1H),7.14-7.04(m,1H),6.78-6.68(m,3H),6.66-6.47(m,6H),3.94-3.82(m,2H),3.31-3.28(m,2H),2.93(s,3H),2.78(br t,J＝5.3Hz,5H),2.74-2.68(m,2H),2.34-2.28(m,2H),2.12-1.96(m,3H)；LCMS:(ESI+)m/z 523.4(M+H) +。
实施例21化合物032的制备
Figure PCTCN2022104551-appb-000071
参照实施例1合成得到白色固体化合物032。
1H NMR:(400MHz,DMSO-d 6)δ9.63-9.17(m,1H),7.46-7.40(m,1H),7.40-7.37(m,1H),7.12-7.07(m,1H),6.77-6.69(m,3H),6.67-6.58(m,3H),6.57-6.48(m,3H),3.93-3.85(m,2H),3.32-3.28(m,2H),3.05-2.97(m,3H),2.88-2.83(m,3H),2.81-2.75(m,2H),2.74-2.69(m,2H),2.57-2.54(m,3H),2.33-2.26(m,2H),1.99(br s,3H)；LCMS:(ESI+)m/z 538.4(M+H) +。
实施例22化合物033的制备
Figure PCTCN2022104551-appb-000072
参照实施例1合成得到白色固体化合物033。
1H NMR:(400MHz,DMSO-d 6)δ9.50(s,1H),8.32(d,J＝6.0Hz,2H),7.09(d,J＝6.0Hz,2H),6.79-6.73(m,2H),6.72-6.67(m,3H),6.66-6.58(m,1H),6.56(s,2H),6.54-6.48(m,1H),3.93(t,J＝5.5Hz,2H),3.01(s,3H),2.85(s,3H),2.81(br t,J＝5.5Hz,2H),2.67(br t,J＝6.0Hz,2H),2.53-2.52(m,2H),2.27(br t,J＝6.8Hz,2H),2.04(br t,J＝6.8Hz,2H)；LCMS：(ESI+)m/z 484.3(M+H) +。
实施例23化合物034的制备
Figure PCTCN2022104551-appb-000073
参照实施例1合成得到白色固体化合物034。
1H NMR:(400MHz,DMSO-d 6)δ8.61-8.51(m,2H),8.43(d,J＝8.3Hz,1H),7.88(dd,J＝5.9,8.1Hz,1H),6.96-6.86(m,5H),6.78(d,J＝2.3Hz,1H),6.69(td,J＝6.8,15.1Hz,1H),6.66-6.62(m,1H),6.62-6.57(m,1H),4.32-4.19(m,2H),3.94(d,J＝6.6Hz,2H),3.47(t,J＝4.7Hz,2H),3.16(s,3H),3.01(s,3H),2.82(br t,J＝7.0Hz,2H),2.50(t,J＝6.9Hz,2H),2.23(br t,J＝6.9Hz,2H)；LCMS：(ESI+)m/z 484.2(M+H) +。
实施例24化合物035的制备
Figure PCTCN2022104551-appb-000074
参照实施例1合成得到白色固体化合物035。
1H NMR:(400MHz,DMSO-d 6)δ9.43(s,1H),9.14-9.02(m,2H),7.06-7.00(m,1H),6.97-6.92(m,1H),6.89-6.82(m,1H),6.78-6.68(m,6H),6.66-6.59(m,1H),6.56(s,2H),4.17-4.09(m,2H),3.86-3.77(m,2H),3.41-3.36(m,2H),3.31-3.26(m,3H),2.80-2.67(m,2H),2.19-2.11(m,5H),2.10-2.01(m,2H),1.14-1.08(m,3H),1.06-0.99(m,3H)；LCMS：(ESI+)m/z 543.5(M+H) +。
实施例25化合物036的制备
Figure PCTCN2022104551-appb-000075
参照实施例1合成得到白色固体化合物036。
1H NMR:(400MHz,DMSO-d 6)δ9.43(s,1H),9.10(br s,2H),7.07-7.01(m,1H),6.98-6.93(m,1H),6.89-6.84(m,1H),6.74-6.69(m,4H),6.65-6.61(m,2H),6.59-6.54(m,2H),4.18-4.10(m,2H),3.87-3.79(m,2H),3.54-3.48(m,2H),3.29(brs,3H),2.70(brs,2H),2.20-2.03(m,8H),1.94-1.87(m,2H),1.83-1.75(m,2H)；LCMS：(ESI+)m/z 541.5(M+H) +。
实施例26化合物037的制备
Figure PCTCN2022104551-appb-000076
参照实施例1合成得到白色固体化合物037。
1H NMR:(400MHz,DMSO-d 6)δ9.47(br s,1H),7.37(dd,J＝2.6,8.9Hz,1H),7.16(dd,J＝6.4,8.4Hz,1H),7.09-6.97(m,1H),6.74(s,1H),6.71(s,2H),6.67(s,2H),6.65-6.61(m,1H),6.55(d,J＝1.0Hz,2H),6.44(d,J＝15.1Hz,1H),3.90(br t,J＝5.6Hz,2H),3.33(br d,J＝4.1Hz,2H),3.31-3.27(m,2H),2.84-2.78(m,2H),2.78-2.68(m,2H),2.52(br s,2H),2.21-2.13(m,2H),2.07(br d,J＝2.9Hz,3H),1.07(br t,J＝7.0Hz,3H),1.02(br t,J＝7.0Hz,3H)；LCMS：(ESI+)m/z 563.5(M+H) +。
实施例27化合物038的制备
Figure PCTCN2022104551-appb-000077
参照实施例1合成得到白色固体化合物038。
1H NMR:(400MHz,DMSO-d 6)δ9.58-9.49(m,1H),7.73-7.64(m,1H),7.35-7.25(m,1H),7.16-7.06(m,1H),6.79-6.71(m,5H),6.67-6.60(m,1H),6.59-6.50(m,3H),4.00-3.91(m,2H),3.05-2.98(m,3H),2.92-2.78(m,6H),2.71-2.65(m,3H),2.32-2.24(m,2H),2.15-2.00(m,3H)；LCMS：(ESI+)m/z 526.5(M+H) +。
实施例28化合物039的制备
Figure PCTCN2022104551-appb-000078
参照实施例1合成得到白色固体化合物039。
1H NMR:(400MHz,DMSO-d 6)δ9.76-9.12(m,2H),7.28-7.21(m,2H),7.19-7.13(m,2H),6.89-6.69(m,6H),6.65-6.50(m,3H),4.24-4.12(m,2H),3.87-3.76(m,2H),3.31-3.22(m,2H),3.10-3.00(m,3H),2.91-2.84(m,3H),2.72-2.64(m,2H),2.31-2.22(m,2H),2.11-2.00(m,2H)；LCMS：(ESI+)m/z 567.5(M+H) +。
实施例29化合物040的制备
Figure PCTCN2022104551-appb-000079
参照实施例1合成得到化合物040。
1H NMR:(400MHz,MeOH-d 4)δ7.65(d,J＝2.3Hz,1H),7.42(dd,J＝2.4,8.8Hz,1H),7.05(dd,J＝6.0,8.4Hz,1H),6.93-6.85(m,3H),6.81-6.75(m,2H),6.72-6.60(m,3H),4.61-4.53(m,2H),3.92(dd,J＝0.8,6.6Hz,2H),3.52-3.44(m,2H),3.15(s,3H),3.01(s,3H),2.92-2.75(m,2H),2.32-2.17(m,7H)；LCMS：(ESI+)m/z 516.4(M+H) +。
实施例30化合物041的制备
Figure PCTCN2022104551-appb-000080
参照实施例1合成得到化合物041。
1H NMR:(400MHz,DMSO-d 6)δ9.70-9.10(m,1H),7.07(dd,J＝6.3,8.3Hz,1H),7.00-6.85(m,2H),6.77-6.68(m,2H),6.67-6.55(m,3H),6.55-6.48(m,1H),6.33-6.24(m,2H),3.95-3.86(m,2H),3.07-2.98(m,3H),2.89-2.84(m,3H),2.83-2.75(m,4H),2.72(br s,2H),2.58-2.57(m,3H),2.20-2.15(m,1H),2.15-2.13(m,3H),2.12-1.91(m,3H)；LCMS：(ESI+)m/z 545.5(M+H) +。
实施例31化合物042的制备
Figure PCTCN2022104551-appb-000081
参照实施例1合成得到化合物042。
1H NMR:(400MHz,DMSO-d 6)δ11.02-10.87(m,1H),9.16-8.99(m,2H),7.36-7.31(m,1H),7.27-7.22(m,1H),7.18-7.12(m,1H),6.91-6.73(m,5H),6.72-6.65(m,3H),6.62-6.53(m,3H),6.32-6.22(m,1H),4.16-4.08(m,2H),3.85-3.79(m,2H),3.28-3.23(m,2H),3.06-3.02(m,3H),2.90-2.86(m,3H),2.72(br d,J＝6.3Hz,2H),2.34-2.31(m,2H),2.11-2.02(m,2H)；LCMS：(ESI+)m/z 522.2(M+H) +。
实施例32化合物043的制备
Figure PCTCN2022104551-appb-000082
参照实施例1合成得到化合物043。
1H NMR:(400MHz,DMSO-d 6)δ9.46-9.36(m,1H),7.30(d,J＝2.1Hz,1H),7.22-7.15(m,1H),6.77-6.61(s,8H),6.56-6.50(m,3H),3.98-3.90(m,2H),3.48-3.42(m,2H),3.04-2.99(m,3H),2.88-2.80(m,5H),2.69-2.64(m,2H),2.23-2.16(m,2H),2.08-2.01(m,2H)；LCMS：(ESI+)m/z 524.5(M+H) +。
实施例33化合物044的制备
Figure PCTCN2022104551-appb-000083
参照实施例1合成得到化合物044。
1H NMR:(400MHz,DMSO-d 6)δ9.49-9.40(m,2H),9.31(d,J＝1.1Hz,1H),8.51-8.46(m,1H),8.34-8.27(m,1H),7.97-7.90(m,2H),7.86-7.82(m,1H),7.30-7.20(m,1H),6.81-6.75(m,2H),6.73-6.70(m,1H),6.67-6.62(m,2H),6.59-6.56(m,2H),6.55-6.46(m,1H),3.98(br s,2H),2.96(s,3H),2.90-2.82(m,3H),2.81-2.75(m,2H),2.74-2.67(m,2H),2.36-2.33(m,2H),2.10-2.04(m,2H)；LCMS：(ESI+)m/z 540.5(M+H) +。
实施例34化合物045的制备
Figure PCTCN2022104551-appb-000084
参照实施例1合成得到化合物045。
1H NMR:(400MHz,DMSO-d 6)δ9.55(s,1H),9.28(br s,2H),7.73(d,J＝7.0Hz,1H),7.30(d,J＝9.6Hz,1H),6.86-6.72(m,6H),6.64-6.52(m,3H),4.17(br t,J＝4.6Hz,2H),3.81(br d,J＝5.5Hz,2H),3.28(br s,2H),3.05(s,3H),2.88(s,3H),2.84-2.71(m,2H),2.17(br d,J＝6.3Hz,2H),2.13-2.04(m,2H))；LCMS：(ESI+)m/z 569.4(M+H) +。
实施例35化合物046的制备
Figure PCTCN2022104551-appb-000085
参照实施例1合成得到化合物046。
1H NMR:(400MHz,DMSO-d 6)δ9.56-9.27(m,1H),7.27-7.09(m,2H),6.97-6.87(m,1H),6.79-6.49(m,9H),4.02-3.85(m,2H),3.31-3.13(m,2H),3.06-2.96(m,3H),2.90-2.77(m,5H),2.72-2.63(m,2H),2.29-2.20(m,2H),2.10-1.99(m,2H)；LCMS:(ESI+)m/z 563.5(M+H) +。
实施例36化合物047的制备
Figure PCTCN2022104551-appb-000086
参照实施例1合成得到化合物047。
1H NMR:(400MHz,DMSO-d 6)δ9.53-9.02(m,3H),7.64(d,J＝2.3Hz,1H),7.37(d,J＝1.4Hz,1H),6.89-6.75(m,5H),6.71-6.68(m,1H),6.62-6.50(m,3H),4.20-4.13(m,2H),3.84-3.79(m,3H),3.77(s,2H),3.34-3.27(m,2H),3.06-3.03(m,3H),2.88-2.85(m,3H),2.67-2.63(m,2H),2.26-2.18(m,2H),2.07-1.98(m,5H)；LCMS:(ESI+)m/z 528.5(M+H) +。
实施例37化合物048的制备
Figure PCTCN2022104551-appb-000087
参照实施例1合成得到化合物048。
1H NMR:(400MHz,DMSO-d 6)δ9.61-9.39(m,1H),9.29-9.09(m,2H),7.74-7.65(m,1H),7.51-7.41(m,1H),6.98-6.75(m,5H),6.74-6.70(m,1H),6.66-6.52(m,3H),4.24-4.16(m,2H),3.89-3.79(m,5H),3.33-3.27(m,2H),3.08-3.03(m,3H),2.91-2.87(m,3H),2.64(br s,2H),2.29-2.21(m,2H),2.13-2.05(m,2H)；LCMS:(ESI+)m/z 532.3(M+H) +。
实施例38化合物049的制备
Figure PCTCN2022104551-appb-000088
参照实施例1合成得到化合物049。
1H NMR:(400MHz,DMSO-d 6)δ9.59-9.40(m,1H),8.31(d,J＝1.9Hz,1H),8.16(d,J＝1.3Hz,1H),7.74(s,1H),6.83-6.69(m,5H),6.51(s,5H),4.00-3.88(m,2H),3.38-3.35(m,2H),3.05-2.99(m,3H),2.88-2.80(m,5H),2.70-2.66(m,2H),2.29-2.24(m,2H),2.10-2.05(m,2H)；LCMS:(ESI+)m/z 518.4(M+H) +。
实施例39化合物050的制备
Figure PCTCN2022104551-appb-000089
参照实施例1合成得到化合物050。
1H NMR:(400MHz,DMSO-d 6)δ9.52(br s,1H),8.36(d,J＝1.5Hz,1H),8.24(d,J＝4.6Hz,1H),7.25(dd,J＝5.2,6.2Hz,1H),6.77-6.72(m,3H),6.71-6.66(m,2H),6.60(s,1H),6.58(s,2H),6.54-6.48(m,1H),3.92(t,J＝5.6Hz,2H),3.01(s,3H),2.85(s,3H),2.80(t,J＝5.6Hz,2H),2.70(br t,J＝6.9Hz,2H),2.52(br s,2H),2.25-2.18(m,2H),2.15-1.90(m,3H)；LCMS:(ESI+)m/z 502.4(M+H) +。
实施例40化合物052的制备
Figure PCTCN2022104551-appb-000090
参照实施例1合成得到化合物052。
1H NMR:(400MHz,DMSO-d 6)δ9.46(s,1H),9.26-8.94(m,2H),7.05(dd,J＝6.3,8.4Hz,1H),6.98(dd,J＝2.5,10.1Hz,1H),6.92(d,J＝8.8Hz,1H),6.91-6.85(m,1H),6.84-6.77(m,2H),6.75-6.68(m,2H),6.64-6.54(m,3H),4.24(br d,J＝3.9Hz,2H),3.88(br d,J＝5.1Hz,2H),3.04(s,3H),2.88(s,3H),2.83-2.69(m,2H),2.52-2.52(m,2H),2.17(s,3H),2.14(br s,2H),2.12-2.06(m,2H)；LCMS:(ESI+)m/z 549.5(M+H) +。
实施例41化合物053的制备
Figure PCTCN2022104551-appb-000091
参照实施例1合成得到化合物053。
1H NMR:(400MHz,DMSO-d 6)δ9.46(s,1H),9.23-8.89(m,2H),7.06(dd,J＝6.2,8.4Hz,1H),7.02-6.93(m,2H),6.89(dt,J＝2.8,8.5Hz,1H),6.81(br d,J＝15.3Hz,1H),6.74(s,1H),6.62-6.54(m,5H),4.23(br s,2H),3.83(br d,J＝5.5Hz,2H),3.05(s,3H),2.89(s,3H),2.82-2.69(m,2H),2.53(br s,2H),2.18(s,3H),2.14(br d,J＝4.6Hz,2H),2.13-2.07(m,2H)；LCMS:(ESI+)m/z 533.4(M+H) +。
实施例42化合物054的制备
Figure PCTCN2022104551-appb-000092
参照实施例1合成得到化合物054。
1H NMR:(400MHz,DMSO-d 6)δ9.40(s,1H),9.06(br d,J＝1.3Hz,2H),7.07-6.90(m,2H),6.89-6.77(m,3H),6.71(s,1H),6.65(dd,J＝2.3,11.7Hz,1H),6.62-6.55(m,2H),6.54(s,2H),4.15(br d,J＝4.3Hz,2H),3.81(br d,J＝5.8Hz,2H),3.28(br s,2H),3.05(s,3H),2.88(s,3H),2.86-2.68(m,2H),2.21(br s,3H),2.19-2.09(m,4H)；LCMS:(ESI+)m/z 533.3(M+H) +。
实施例43化合物055的制备
Figure PCTCN2022104551-appb-000093
参照实施例1合成得到化合物055。
1H NMR:(400MHz,DMSO-d 6)δ9.45(br s,3H),7.05-6.82(m,3H),6.82-6.67(m,3H),6.66-6.57(m,1H),6.57-6.42(m,2H),6.41-6.21(m,2H),4.17(br t,J＝4.6Hz,2H),3.80(br d,J＝5.1Hz,2H),3.56-3.43(m,3H),3.25(br s,2H),3.05(s,3H),3.02-2.78(m,4H),2.76-2.55(m,1H),2.26-2.17(m,3H),2.17-1.91(m,4H)；LCMS:(ESI+)m/z 545.5(M+H) +。
实施例44化合物056的制备
Figure PCTCN2022104551-appb-000094
参照实施例1合成得到化合物056。
1H NMR:(400MHz,DMSO-d 6)δ9.50(s,1H),7.07-6.97(m,2H),6.92-6.85(m,1H),6.74-6.70(m,1H),6.64-6.56(m,3H),6.47(s,1H),6.46-6.38(m,2H),4.08-4.01(m,2H),3.31-3.27(m,2H),3.03-2.96(m,3H),2.88-2.82(m,3H),2.79-2.63(m,4H),2.18-2.05(m,7H)；LCMS:(ESI+)m/z 551.5(M+H) +。
实施例45化合物057的制备
Figure PCTCN2022104551-appb-000095
参照实施例1合成得到化合物057。
1H NMR:(400MHz,DMSO-d 6)δ9.45(s,1H),7.07-6.92(m,2H),6.82-6.71(m,4H),6.69(d,J＝1.6Hz,1H),6.67-6.58(m,1H),6.58-6.48(m,3H),4.05(q,J＝7.0Hz,2H),3.95(t,J＝5.6Hz,2H),3.01(s,3H),2.85(s,3H),2.82(br t,J＝5.6Hz,2H),2.70-2.64(m,2H),2.52(br d,J＝1.9Hz,2H),2.27-2.20(m,2H),2.10-2.01(m,2H),1.27(t,J＝7.0Hz,3H)；LCMS:(ESI+)m/z 579.4(M+H) +。
实施例46化合物059的制备
Figure PCTCN2022104551-appb-000096
参照实施例1合成得到化合物059。
1H NMR:(400MHz,DMSO-d 6)δ9.54-9.44(m,1H),7.72-7.62(m,1H),6.85(br t,J＝7.6Hz,3H),6.74-6.70(m,1H),6.65-6.47(m,5H),4.22-4.13(m,2H),3.32(br d,J＝5.0Hz,3H),3.03-2.97(m,3H),2.72(br d,J＝5.8Hz,7H),2.26-2.09(m,6H)；LCMS:(ESI+)m/z 534.5(M+H) +。
实施例47化合物060的制备
Figure PCTCN2022104551-appb-000097
参照实施例1合成得到化合物060。
1H NMR:(400MHz,DMSO-d 6)δ9.52-9.39(m,1H),7.78-7.67(m,1H),7.28-7.00(m,1H),6.79(dt,J＝2.4,8.5Hz,3H),6.73-6.70(m,1H),6.65-6.57(m,1H),6.56-6.47(m,3H),4.24-4.12(m,2H),3.31(br s,3H),2.95(br s,4H),2.89(br s,3H),2.81-2.74(m,2H),2.68-2.57(m,1H),2.35-2.24(m,3H),2.21-2.06(m,4H)；LCMS:(ESI+)m/z 550.4(M+H) +。
实施例48化合物062的制备
Figure PCTCN2022104551-appb-000098
参照实施例1合成得到化合物062。
1H NMR:(400MHz,DMSO-d 6)δ7.01(dd,J＝6.1,8.3Hz,1H),6.91(d,J＝8.5Hz,1H),6.88-6.49(m,9H),4.01(br t,J＝4.8Hz,2H),3.47(d,J＝5.6Hz,2H),3.29-3.14(m,1H),3.12(s,3H),3.06-2.94(m,5H),2.78-2.57(m,1H),2.42-2.10(m,7H)；LCMS:(ESI+)m/z 549.2(M+H) +。
实施例49化合物063的制备
Figure PCTCN2022104551-appb-000099
参照实施例1合成得到化合物063。
1H NMR(400MHz,DMSO-d 6)δ9.48(s,1H),7.50(s,1H),7.44–7.39(m,1H),7.27(d,J＝7.9Hz,1H),6.75(t,J＝1.4Hz,1H),6.73–6.65(m,4H),6.65–6.51(m,4H),3.93(t,J＝5.6Hz,2H),3.03(s,3H),2.88(s,3H),2.82(t,J＝5.5Hz,2H),2.80–2.71(m,2H),2.26(s,3H),2.19(t,J＝5.9Hz,2H),2.11(d,J＝6.7Hz,2H),1.27(s,2H).LCMS:(ESI+)m/z 565.5(M+H) +。
实施例50化合物064的制备
Figure PCTCN2022104551-appb-000100
参照实施例1合成得到化合物064。
1H NMR(400MHz,Methanol-d 4)δ8.51(s,1H),7.95(d,J＝5.3Hz,1H),7.09(d,J＝5.4Hz,1H),6.91(d,J＝8.1Hz,2H),6.88–6.80(m,4H),6.78(d,J＝3.3Hz,2H),6.67(d,J＝8.3Hz,1H),6.65–6.60(m,1H),4.19(t,J＝5.0Hz,2H),3.74(t,J＝2.3Hz,2H),3.26(t,J＝5.1Hz,2H),3.18(s,3H),3.04(s,3H),2.79(t,J＝7.1Hz,2H),2.44(t,J＝7.0Hz,2H),2.20(d,J＝8.0Hz,2H).LCMS:(ESI+)m/z 502.5(M+H) +。
实施例51化合物065的制备
Figure PCTCN2022104551-appb-000101
参照实施例1合成得到化合物065。
1H NMR(400MHz,Methanol-d4)δ8.56(s,1H),8.31–8.15(m,2H),7.17(d,J＝5.1Hz,1H),6.85–6.60(m,9H),4.11(t,J＝5.1Hz,2H),3.65(d,J＝5.5Hz,2H),3.16(d,J＝4.1Hz,5H),3.03(s,3H),2.86(t,J＝7.1Hz,2H),2.32(d,J＝7.1Hz,2H),2.19(s,5H).LCMS:(ESI+)m/z 498.6(M+H) +。
实施例52化合物066的制备
Figure PCTCN2022104551-appb-000102
参照实施例1合成得到化合物066。
1H NMR(400MHz,Methanol-d4)δ7.41(dd,J＝9.4,2.8Hz,1H),7.15(dt,J＝19.5,5.2Hz,2H),6.95–6.47(m,9H),4.03(t,J＝5.0Hz,2H),3.50(d,J＝5.7Hz,2H),3.14(s,3H),3.01(s,3H),2.98(d,J＝5.5Hz,2H),2.72(d,J＝12.6Hz,2H),2.36–2.12(m,4H).LCMS:(ESI+)m/z 569.5(M+H) +。
实施例53化合物067的制备
Figure PCTCN2022104551-appb-000103
参照实施例1合成得到化合物067。
1H NMR(400MHz,DMSO-d6)δ8.22(s,1H),7.73(d,J＝10.6Hz,1H),7.39–7.01(m,3H),6.97(dd,J＝8.5,1.9Hz,1H),6.72(d,J＝2.2Hz,1H),6.65–6.55(m,4H),6.51(d,J＝15.2Hz,1H),4.23(t,J＝5.7Hz,2H),3.40-3.30(m,3H),3.01(s,3H),2.85(s,3H),2.81(t,J＝5.8Hz,2H),2.71(t,J＝7.0Hz,2H),2.30(t,J＝7.0Hz,2H),2.17–2.08(m,2H).LCMS:(ESI+)m/z 586.5(M+H) +。
实施例54化合物068的制备
Figure PCTCN2022104551-appb-000104
参照实施例1合成得到化合物068。
1H NMR(400MHz,DMSO-d6)δ8.21(s,1H),7.68(d,J＝10.7Hz,1H),7.51(s,1H),7.39(d,J＝7.9Hz,1H),7.23(s,1H),6.74(d,J＝2.4Hz,1H),6.64–6.53(m,4H),6.50(d,J＝15.2Hz,1H),4.18(t,J＝5.7Hz,2H),3.31(s,2H),3.30(s,2H),3.00(s,3H),2.85(s,3H),2.78(t,J＝5.7Hz,2H),2.30(s,3H),2.22(t,J＝5.6Hz,2H),2.14(t,J＝6.3Hz,2H).LCMS:(ESI+)m/z 584.5(M+H) +。
实施例55化合物069的制备
Figure PCTCN2022104551-appb-000105
参照实施例1合成得到化合物069。
1H NMR(400MHz,DMSO-d6)δ9.48(s,1H),7.72(d,J＝10.6Hz,1H),7.27(d,J＝1.7Hz,1H),7.21(d,J＝8.3Hz,1H),6.91(dd,J＝8.3,1.7Hz,1H),6.71(d,J＝2.2Hz,1H),6.62–6.55(m,4H),6.54–66.48(m,1H),4.22(t,J＝5.7Hz,2H),3.28(s,2H),3.01(s,3H),2.85(s,3H),2.80(t,J＝5.7Hz,2H),2.72(t,J＝7.0Hz,2H),2.33–2.26(m,2H),2.12(t,J＝7.0Hz,2H).LCMS:(ESI+)m/z 582.5(M+H) +。
实施例56化合物070的制备
Figure PCTCN2022104551-appb-000106
参照实施例1合成得到化合物070。
1H NMR(400MHz,DMSO-d 6)8.23(s,1H),7.68(d,J＝10.6Hz,1H),7.59(dd,J＝9.3,2.7Hz,1H),7.40(td,J＝8.3,2.7Hz,1H),7.34(d,J＝6.8Hz,1H),6.72(d,J＝2.4Hz,1H),6.65–6.48(m,5H),4.19(t,J＝5.8Hz,2H),3.32(d,J＝1.5Hz,3H),3.00(s,3H),2.85(s,3H),2.79(t,J＝5.7Hz,2H),2.70(dt,J＝12.0,5.0Hz,1H),2.30–2.11(m,4H).LCMS:(ESI+)m/z 588.5(M+H) +。
实施例57化合物071的制备
Figure PCTCN2022104551-appb-000107
参照实施例1合成得到化合物071。
1H NMR(400MHz,DMSO-d 6)δ9.58(s,1H),8.50(d,J＝2.1Hz,1H),8.25(s,1H),7.87(dd,J＝8.1,2.1Hz,1H),7.81–7.72(m,2H),6.75(d,J＝2.3Hz,1H),6.66–6.57(m,4H),6.51(dt,J＝15.1,1.5Hz,1H),4.22(t,J＝5.7Hz,2H),3.25-3.10(m,2H),3.01(s,3H),2.85(s,3H),2.81(t,J＝5.8Hz,2H),2.75(t,J＝7.0Hz,2H),2.37(t,J＝7.0Hz,2H),2.15(t,J＝7.0Hz,2H).LCMS:(ESI+)m/z 571.4(M+H) +。
实施例58化合物072的制备
Figure PCTCN2022104551-appb-000108
参照实施例1合成得到化合物072。
1H NMR(400MHz,Methanol-d4)δ7.41(d,J＝2.0Hz,1H),7.13–7.03(m,1H),6.93(dd,J＝11.6,2.1Hz,2H),6.87–6.74(m,3H),6.74–6.61(m,3H),4.47(t,J＝5.4Hz,2H),3.66–3.55(m,2H),3.14(d,J＝13.8Hz,5H),3.03(s,3H),2.93–2.77(m,2H),2.37–2.27(m,5H),2.22(t,J＝6.8Hz,2H).LCMS:(ESI+)m/z 534.5(M+H) +。
实施例59化合物073的制备
Figure PCTCN2022104551-appb-000109
参照实施例1合成得到化合物073。
1H NMR(400MHz,Methanol-d 4)δ7.48(d,J＝1.8Hz,1H),7.01(m,2H),6.99(s,1H),6.97 (m,1H),6.73(m,1H),6.66(s,1H),6.64(m,1H),6.58(m,1H),6.35(m,1H),3.69(m,3H),3.68–3.63(m,2H),3.59(s,3H),3.52(m,1H),3.16(m,3H),3.09(m,2H),3.03m,3H),2.46–2.35(m,2H),2.22(m,2H).LCMS:(ESI+)m/z 594.2(M+H) +。
生物活性评价
本发明的化合物选择性抑制雌激素受体活性的抑制能力和对雌激素受体野生型、Y537S及D538G突变体的人乳腺癌细胞株MCF-7细胞株的抗增殖活性，本文所述的生物活性评价可通过如下实验中的测试来证明。
本实验基于核受体(NR)激动剂依赖的共激活肽募集反应原理：通过抗原-抗体反应将Tb标记于NR，Agonist与NR的结合导致其构象的改变，进而导致NR与共激活肽亲和力的增加。共激活肽(FITC)与NR(Tb)两者靠近则产生FRET信号。基于以上反应来评价本申请中化合物对ERα蛋白的抑制活性。
将5μL测试化合物与10nM的ERα蛋白(5μL)分别加入到384孔板中，化合物10μM起始，5倍稀释，9个浓度点，三复孔，并设置对照孔和空白孔。对照孔不加化合物，空白孔不加蛋白，DMSO的终浓度为1％。室温反应15min后，分别加入1test Tb抗体和500nM多肽，两者各5μL。体系混匀后，室温反应24h，读取TR-FRET值。334nm激发，492nm发射；334nm激发，520nm发射；延迟200μs、积分100μs。进而计算各浓度下的抑制率，IC 50由GraphPadPrism 7.0软件拟合得到。
表1测试化合物对ERα蛋白抑制活性(IC 50)
化合物编号 活性 化合物编号 活性 化合物编号 活性
001 ** 002 ** 003 **
004 ** 005 ** 006 **
007 ** 008 * 009 **
010 *** 011 * 012 **
013 ** 014 * 015 *
016 * 017 * 018 **
030 ** 031 ** 032 **
033 *** 034 *** 035 **
036 ** 037 ** 038 **
039 * 040 * 041 **
042 ND 043 ** 044 **
045 * 046 ** 047 **
048 ** 049 ND 050 ***
052 * 053 ** 054 **
055 ** 056 ND 057 *
059 * 060 ** 062 *
063 * 064 ** 065 *
066 ** 067 ** 068 *
069 ** 070 ** 071 **
072 ** 073 *    
上述列表中活性小于***表示为<10nM；**表示为大于>10nM，<100nM；*表示为>100nM。
采用CCK8评价测试化合物对人乳腺癌细胞株MCF-7-ERα(WT、Y537S、D538G)点突变稳转单克隆细胞株的抗增殖活性。取上述生长正常的细胞，用胰酶细胞消化液进行消化，离心，计数，以5000个/孔的细胞密度铺到96孔板中，每孔100μL。细胞铺板后第二天进行给药，每孔加不同浓度梯度的化合物，每个浓度点设三个复孔，另外设置相应的DMSO阴性处理对照组。药物处理72h后，每孔加入CCK8溶液，37℃孵育一段时间后(Vehicle组OD450达到1.0以上)，读取酶标仪450nm处的吸收，计算抑制率，IC50值由GraphPad Prism 7.0软件拟合得到。
表2测试化合物对MCF-7-ERα/WT细胞株增殖抑制活性(IC 50)
化合物编号 MCF7-WT MCF7-537S MCF7-538G
001 ND ** **
002 *** ** ***
003 *** ** ***
004 *** ** ***
005 *** *** ***
006 *** *** ***
007 *** *** ***
008 *** ** **
009 *** *** ***
010 *** *** ***
011 ND ** ***
012 *** *** **
013 ND ** ***
014 ND ** **
015 ND ** ***
016 ND ** ***
017 ND ** ***
018 ND ** ***
030 ND *** ND
031 ND ** ND
032 ND *** ND
033 ND *** ND
034 ND ** ND
035 ND *** ND
036 ND *** ND
037 ND *** ND
038 ND ** ND
039 ND *** ND
040 ND *** ND
041 ND *** ND
042 ND ** ND
043 ND ** ND
044 ND ** ND
045 ND *** ND
046 ND *** ND
047 ND ** ND
048 ND *** ND
049 ND *** ND
050 ND *** ND
053 ND ** ND
054 ND *** ND
055 ND *** ND
056 ND *** ND
057 ND ** ND
059 ND *** ND
上述列表中ND表示未测试；活性小于***表示为<10nM；**表示为大于>10nM，<100nM；*表示为>100nM。
应当理解，以上实施例均为示例性的，不用于包含权利要求所包含的所有可能的实施方式。在不脱离本公开的范围的情况下，还可以在以上实施例的基础上做出各种变形和改变。同样的，也可以对以上实施例的各个技术特征进行任意组合，以形成可能没有被明确描述的本发明的另外的实施例。因此，上述实施例仅表达了本发明的几种实施方式，不对本发明专利的保护范围进行限制。

Claims (15)

  1. 一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，所述式(Ⅰ)化合物的结构为：
    Figure PCTCN2022104551-appb-100001
    其中，
    每一个R 1独立地选自-H,D,-OH,-NH 2,-COOH,-CH 2NH 2和-CH 2OH；
    R 2选自取代或未取代的芳基、杂环基和杂芳基；
    R 3选自-(CH 2) pCH＝CHCONR 4R 5和-COCH＝CR 6R 7，其中，
    R 4，R 5，R 6，R 7分别独立地选自-H、D、烷基、环烷基和杂环基；
    或R 4与R 5以及相连的氮原子形成3-7元杂环基，或R 6和R 7以及相连的碳原子形成C 3-6环烷基或3-7元杂环基；
    p选自0,1,2和3；
    Z选自O、S、CHR 11和NH，R 11可以为H,OH,D,NH 2和C 1-3烷基；
    Y选自-R 8NH-、-(CR 9R 10) qNH-和3-7元含氮杂环基，其中，
    R 8为C 3-6环烷基或3-7元杂环基；
    每一个R 9和R 10分别独立地选自-H、卤素原子、取代或未取代的C 1-6烷基和C 3-6环烷基；或R 9和R 10以及与其相连的碳原子形成取代或未取代的C 3-6环烷基或3-7元杂环基；或R 9或R 10、与R 9或R 10的碳原子以及与所述碳原子相邻的碳原子形成C 3-6环烷基；
    q选自1,2,3,4和5；
    Figure PCTCN2022104551-appb-100002
    选自取代或未取代的芳基和杂芳基；
    m选自1,2,3和4。
  2. 根据权利要求1所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，其特征在于，
    R 2选自取代或未取代的苯基、3-9元杂环基和5-10元杂芳基，所述取代是被选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨基、C 3-6 环烷基、C 6-10芳基、5-10元杂芳基或3-7元杂环基中的一个或多个取代基所取代，上述取代基任选被1-3个选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基所取代。
  3. 根据权利要求2所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，其特征在于，
    所述3-9元杂环基选自氮丙啶基、氮杂环丁基、氧杂环丁基、吡咯烷基、四氢呋喃基、四氢噻吩基、哌啶基、吗啉基、哌嗪基、硫代吗啉基、四氢吡喃基、1,1-二氧硫代吗啉基、丁内酰胺基、戊内酰胺基、己内酰胺基、丁内酯基、戊内酯基、己内酯基、2,3-二氢-1H-吲哚基和苯并二氧戊环基中的任一种；
    所述5-10元杂芳基含有1-3个任选自N、NH、O、S的杂原子；优选的，所述5-10元杂芳环选自噻吩基、吡啶基、嘧啶基、吡嗪基、哒嗪基、吡咯基、吡唑基、噻唑基、1，2，3-三唑基、1，2，4-三唑基、咪唑基、四氮唑基、异噻唑基、噁唑基、异噁唑基、噻二唑基、噁二唑基、苯并噻吩基、吲哚基、苯并咪唑基、苯并噻唑基、苯并吡唑、苯并呋喃基、苯并噁唑基、苯并异噁唑基、喹啉基、异喹啉基、喹唑啉基、吲唑基或吲哚[1,2-a]吡嗪基中的任一种。
  4. 根据权利要求1所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，其特征在于，
    R 3选自-(CH 2) pCH＝CHCONR 4R 5和-COCH＝CR 6R 7，其中，
    R 4，R 5，R 6，R 7分别独立地选自-H、D、C 1-3烷基、C 3-6环烷基和5-6元杂环基；
    或R 4与R 5以及相连的氮原子形成5-6元杂环基；
    p为1。
  5. 根据权利要求1所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，其特征在于，
    Y选自-R 8NH-、-(CR 9R 10) qNH-和4-6元含氮杂环基，其中，
    R 8为C 3-6环烷基或4-6元杂环基；
    每一个R 9和R 10分别独立地选自-H、卤素原子、取代或未取代的C 1-6烷基和C 3-6环烷基；或R 9和R 10以及与其相连的碳原子形成C 3-6环烷基或3-7元杂环基；或R 9或R 10、与R 9或R 10的碳原子以及与所述碳原子相邻的碳原子形成C 3-6环烷基；所述取代的C 1-6烷基和C 3-6环烷基是被选自卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基和C 1-6烷氨基的取代基所取代；
    q选自1,2和3，优选为2。
  6. 根据权利要求1所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，其特征在于，
    Figure PCTCN2022104551-appb-100003
    选自取代或未取代的C 6-10芳基和5-10元杂芳基，所述取代是被选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基、C 6-10芳基、5-10元杂芳基或3-7元杂环基中的一个或多个取代基所取代，上述取代基任选被1-3个选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基所取代。
  7. 根据权利要求6所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，其特征在于，
    Figure PCTCN2022104551-appb-100004
    选自取代或未取代的苯基和吡啶基，所述取代是被选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基、C 6-10芳基、5-10元杂芳基或3-7元杂环基中的一个或多个取代基所取代，上述取代基任选被1-3个选自C 1-6烷基、卤素原子、-NH 2、-CN、-COOH、-CHO、-OH、-NO 2、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基所取代。
  8. 根据权利要求1所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，其特征在于，所述化合物的结构如式Ⅱ所示：
    Figure PCTCN2022104551-appb-100005
    其中，
    R 1独立地选自-H,-OH和-NH 2；
    R 2选自取代或未取代的苯基、C 5-10杂芳基；所述取代是被选自卤素、氰基、C 1-3烷氧基、卤素取代的C 1-3烷氧基的取代基所取代；
    R 3选自-CH 2CH＝CHCONR 4R 5，其中，
    R 4，R 5分别独立地选自-H和C 1-3烷基；或R 4与R 5以及相连的氮原子形成吡咯烷基或哌 啶基；
    Z选自O、S和NH；
    Y选自-R 8NH-、-(CR 9R 10) qNH-和3-7元含氮杂环基，其中，
    R 8为C 3-6环烷基；
    每一个R 9和R 10分别独立地选自-H、卤素原子、C 1-3烷基；或R 9和R 10以及与其相连的碳原子形成C 3-6环烷基；
    q为2；
    Figure PCTCN2022104551-appb-100006
    选自取代或未取代的苯基和吡啶基，所述取代是被选自-H、卤素原子和C 1-3烷氧基的取代基所取代。
  9. 一种化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，其特征在于，所述化合物选自：
    Figure PCTCN2022104551-appb-100007
    Figure PCTCN2022104551-appb-100008
    Figure PCTCN2022104551-appb-100009
    Figure PCTCN2022104551-appb-100010
  10. 一种药物组合物，其包含权利要求1-9任一项所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物。
  11. 权利要求1至9中任一项所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，或者权利要求10所述的药物组合物，其用作预防和/或治疗雌激素受体介导的或依赖性的疾病和病症。
  12. 权利要求1至9中任一项所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，或者权利要求10所述的药物组合物用作预防和/或治疗雌激素受体介导的或依赖性的疾病和病症的用途。
  13. 权利要求1至9中任一项所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，或者权利要求10所述的药物组合物在制备预防和/或治疗雌激素受体介导的或依赖性的疾病和病症的药物中的应用。
  14. 一种预防和/或治疗雌激素受体介导的或依赖性的疾病和病症的方法，其包括下列步骤：将治疗有效量的根据权利要求1至9中任一项所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，或者权利要求10所述的药物组合物施用于对其有需求的患者。
  15. 一种药物联合形式，其包含权利要求1至9中任一项所述的一种式(Ⅰ)化合物或其药学上可接受的盐、酯、异构体、溶剂化物、前药或同位素标记物，或者权利要求10所述的药物组合物，以及至少一种额外的治疗剂。
PCT/CN2022/104551 2021-07-08 2022-07-08 一类苯并七元环类化合物及其应用 WO2023280295A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202110772665 2021-07-08
CN202110772665.4 2021-07-08
CN202210680559.8 2022-06-16
CN202210680559 2022-06-16

Publications (1)

Publication Number Publication Date
WO2023280295A1 true WO2023280295A1 (zh) 2023-01-12

Family

ID=84800317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/104551 WO2023280295A1 (zh) 2021-07-08 2022-07-08 一类苯并七元环类化合物及其应用

Country Status (3)

Country Link
CN (1) CN115594607A (zh)
TW (1) TW202313558A (zh)
WO (1) WO2023280295A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1309635A (zh) * 1998-07-18 2001-08-22 舍林股份公司 苯并环庚烯,其制备方法,包含该化合物的药物制剂以及在制备药物中的应用
CN108884079A (zh) * 2016-02-15 2018-11-23 赛诺菲 作为雌激素受体调节剂的6,7-二氢-5h-苯并[7]轮烯衍生物
CN109963848A (zh) * 2016-11-17 2019-07-02 赛诺菲 新颖的取代的n-(3-氟丙基)-吡咯烷化合物、其制备方法以及其治疗用途
CN112105607A (zh) * 2018-01-22 2020-12-18 雷迪厄斯制药公司 雌激素受体调节化合物
WO2021063967A1 (en) * 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863911A (en) * 1994-10-12 1999-01-26 Modelisation Et Mise Au Point De Molecules Medicinales Diarylethylene metallocene derivatives, their processes of preparation and pharmaceutical compositions containing said derivatives
EP1417169A2 (en) * 2001-08-11 2004-05-12 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
IL161322A0 (en) * 2001-10-12 2004-09-27 Schering Ag Synthesis of oxygen-substituted benzocycloheptenes, used as valuable intermediate products for producing tissue-selective oestrogens
JP6807841B2 (ja) * 2014-12-18 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーター及びその使用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1309635A (zh) * 1998-07-18 2001-08-22 舍林股份公司 苯并环庚烯,其制备方法,包含该化合物的药物制剂以及在制备药物中的应用
CN108884079A (zh) * 2016-02-15 2018-11-23 赛诺菲 作为雌激素受体调节剂的6,7-二氢-5h-苯并[7]轮烯衍生物
CN109963848A (zh) * 2016-11-17 2019-07-02 赛诺菲 新颖的取代的n-(3-氟丙基)-吡咯烷化合物、其制备方法以及其治疗用途
CN112105607A (zh) * 2018-01-22 2020-12-18 雷迪厄斯制药公司 雌激素受体调节化合物
WO2021063967A1 (en) * 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof

Also Published As

Publication number Publication date
TW202313558A (zh) 2023-04-01
CN115594607A (zh) 2023-01-13

Similar Documents

Publication Publication Date Title
JP6717457B2 (ja) Ｗｅｅ１阻害剤としての１，２−ジヒドロ−３Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−３−オン誘導体
CN109153636B (zh) 作为双重lsd1/hdac抑制剂的环丙基-酰胺化合物
JP6861858B2 (ja) Ｓｓａｏ阻害剤
CA3133753A1 (en) Novel small molecule inhibitors of tead transcription factors
AU2009247262B2 (en) Amide compound
JP2022503942A (ja) イソインドリン化合物、その調製方法、医薬組成物および使用
CA2555800C (en) Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists
US6187782B1 (en) Morphinane derivatives and medicinal use thereof
WO2019085933A1 (zh) 作为Wee1抑制剂的大环类化合物及其应用
CN114616232A (zh) 氮杂环庚烷并嘧啶类衍生物及其医药用途
JP2011519858A (ja) プロリルヒドロキシラ−ゼ阻害剤
EP4037768B1 (en) Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
RU2722441C2 (ru) Замещённые индольные соединения в качестве понижающих регуляторов рецепторов эстрогена
JP2016538250A (ja) ジアリールアルキルアミンｒｅｖ−ｅｒｂアンタゴニストおよびそれらの医薬品としての使用
EP4206197A1 (en) Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method
JPH01311063A (ja) ヘテラ―脂肪族カルボクサミド誘導体、その製造方法、該化合物の中間体および該化合物を含有するロイコトリエン拮抗作用を有する薬学的組成物
TW201925211A (zh) 用於製備苯并噻吩-2-基硼酸酯之方法
WO2023280295A1 (zh) 一类苯并七元环类化合物及其应用
KR20200118008A (ko) 테트라하이드로피롤계 화합물, 그의 제조방법, 약학조성물 및 용도
ES2257168A1 (es) Ligandos del receptor 5-ht7.
AU2019400398B2 (en) Estrogen receptor antagonist
JP2024520969A (ja) Ｗｅｅ１阻害剤とその用途
CN111205244B (zh) 噻唑并环类化合物、其制备方法、中间体和应用
JP2001525398A (ja) 選択的β３アドレナリン作動性アゴニスト
TWI454470B (zh) 硫苯並薁丙酸衍生物之製造法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22837040

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22837040

Country of ref document: EP

Kind code of ref document: A1